<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Immunol</journal-id><journal-id journal-id-type="iso-abbrev">Front Immunol</journal-id><journal-id journal-id-type="pmc-domain-id">1754</journal-id><journal-id journal-id-type="pmc-domain">frontimmu</journal-id><journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id><journal-title-group><journal-title>Frontiers in Immunology</journal-title></journal-title-group><issn pub-type="epub">1664-3224</issn><publisher><publisher-name>Frontiers Media SA</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC7240201</article-id><article-id pub-id-type="pmcid-ver">PMC7240201.1</article-id><article-id pub-id-type="pmcaid">7240201</article-id><article-id pub-id-type="pmcaiid">7240201</article-id><article-id pub-id-type="pmid">32477334</article-id><article-id pub-id-type="doi">10.3389/fimmu.2020.00791</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Immunology</subject><subj-group><subject>Review</subject></subj-group></subj-group></article-categories><title-group><article-title>Immunogenicity of Protein Therapeutics: A Lymph Node Perspective</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Fu</surname><given-names initials="K">Kristy</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="author-notes" rid="fn002"><sup>&#8224;</sup></xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>March</surname><given-names initials="K">Kylie</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="author-notes" rid="fn002"><sup>&#8224;</sup></xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://loop.frontiersin.org/people/880757/overview"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Alexaki</surname><given-names initials="A">Aikaterini</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://loop.frontiersin.org/people/682654/overview"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Fabozzi</surname><given-names initials="G">Giulia</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://loop.frontiersin.org/people/664894/overview"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Moysi</surname><given-names initials="E">Eirini</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Petrovas</surname><given-names initials="C">Constantinos</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="c001"><sup>*</sup></xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://loop.frontiersin.org/people/438619/overview"/></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Tissue Analysis Core, Immunology Laboratory, Vaccine Research Center, NIAID, National Institutes of Health (NIH)</institution>, <addr-line>Bethesda, MD</addr-line>, <country>United States</country></aff><aff id="aff2"><sup>2</sup><institution>Center for Biologics Evaluation and Research, Food and Drug Administration</institution>, <addr-line>Silver Spring, MD</addr-line>, <country>United States</country></aff><author-notes><fn fn-type="edited-by"><p>Edited by: Amy Rosenberg, United States Food and Drug Administration, United States</p></fn><fn fn-type="edited-by"><p>Reviewed by: Wayne Robert Thomas, University of Western Australia, Australia; Srinivasa Reddy Bonam, &#201;cole Sup&#233;rieure de Biotechnologie Strasbourg (ESBS), France</p></fn><corresp id="c001">*Correspondence: Constantinos Petrovas <email>petrovasc@mail.nih.gov</email></corresp><fn fn-type="other" id="fn001"><p>This article was submitted to Vaccines and Molecular Therapeutics, a section of the journal Frontiers in Immunology</p></fn><fn fn-type="other" id="fn002"><p>&#8224;These authors have contributed equally to this work</p></fn></author-notes><pub-date pub-type="epub"><day>14</day><month>5</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><volume>11</volume><issue-id pub-id-type="pmc-issue-id">351098</issue-id><elocation-id>791</elocation-id><history><date date-type="received"><day>03</day><month>1</month><year>2020</year></date><date date-type="accepted"><day>07</day><month>4</month><year>2020</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>01</month><year>2020</year></date></event><event event-type="pmc-live"><date><day>29</day><month>05</month><year>2020</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2020-06-03 04:56:19.780"><day>03</day><month>06</month><year>2020</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2020 Fu, March, Alexaki, Fabozzi, Moysi and Petrovas.</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Fu, March, Alexaki, Fabozzi, Moysi and Petrovas</copyright-holder><license xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="fimmu-11-00791.pdf"/><abstract><p>The continuous development of molecular biology and protein engineering technologies enables the expansion of the breadth and complexity of protein therapeutics for <italic toggle="yes">in vivo</italic> administration. However, the immunogenicity and associated <italic toggle="yes">in vivo</italic> development of antibodies against therapeutics are a major restriction factor for their usage. The B cell follicular and particularly germinal center areas in secondary lymphoid organs are the anatomical sites where the development of antibody responses against pathogens and immunogens takes place. A growing body of data has revealed the importance of the orchestrated function of highly differentiated adaptive immunity cells, including follicular helper CD4 T cells and germinal center B cells, for the optimal generation of these antibody responses. Understanding the cellular and molecular mechanisms mediating the antibody responses against therapeutics could lead to novel strategies to reduce their immunogenicity and increase their efficacy.</p></abstract><kwd-group><kwd>therapeutics</kwd><kwd>follicle</kwd><kwd>germinal center</kwd><kwd>B cells</kwd><kwd>ADA</kwd><kwd>Tfh cell</kwd></kwd-group><funding-group><award-group><funding-source id="cn001">National Institutes of Health<named-content content-type="fundref-id">10.13039/100000002</named-content></funding-source><award-id rid="cn001">OP1032325</award-id></award-group></funding-group><counts><fig-count count="1"/><table-count count="1"/><equation-count count="0"/><ref-count count="164"/><page-count count="10"/><word-count count="8935"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s1"><title>Introduction</title><p>Protein therapeutics is a new class of drugs that, unlike small molecule drugs, are not chemically synthesized; instead, they are produced within living cells or organisms. Remarkable developments in molecular biology and protein engineering methodologies in the last few decades have enabled the generation of several new biotherapeutics for a wide range of diseases. Despite the potential of protein therapeutics, a drawback, often associated with them, is the generation of antidrug antibodies (ADAs), which diminishes the bioactivity and effectiveness of the therapeutic (<xref rid="B1" ref-type="bibr">1</xref>). The anatomical sites where the development of ADA occurs are the secondary lymphoid organs, including lymph nodes and spleen, which are central for humoral responses to immunogens and pathogens (<xref rid="B2" ref-type="bibr">2</xref>&#8211;<xref rid="B4" ref-type="bibr">4</xref>). The organogenesis (<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B6" ref-type="bibr">6</xref>), architecture (<xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B8" ref-type="bibr">8</xref>), and cellular composition (<xref rid="B9" ref-type="bibr">9</xref>, <xref rid="B10" ref-type="bibr">10</xref>) of lymph nodes as well as the immune reactions to pathogens mediating the development of humoral responses (<xref rid="B11" ref-type="bibr">11</xref>, <xref rid="B12" ref-type="bibr">12</xref>) are well-studied and understood. Here, we review these principles with a focus on ADA development and potential strategies aiming to minimize the immunogenicity of biotherapeutics.</p></sec><sec id="s2"><title>Historical Background</title><p>The history of protein therapeutics starts probably with diphtheria antitoxin derived from horse serum. The extraction of insulin from bovine pancreas, a few decades later, was a milestone in the treatment of diabetes. The development and approval of recombinant insulin, a human insulin expressed in <italic toggle="yes">Escherichia coli</italic>, in 1982 (<xref rid="B13" ref-type="bibr">13</xref>) resulted in the increased accessibility of insulin. Around the same time, murine monoclonal antibodies were being considered as therapeutic agents, with Orthoclone OKT3 (muromonab-CD3) being the first licensed monoclonal antibody, in 1986 (<xref rid="B14" ref-type="bibr">14</xref>). Many of the first-generation monoclonal antibodies were significantly immunogenic, because of their murine origin. Orthoclone OKT3 was eventually discontinued from the market in 2010 owing to the development of ADA (<xref rid="B14" ref-type="bibr">14</xref>&#8211;<xref rid="B17" ref-type="bibr">17</xref>). New generations of monoclonal antibodies are primarily being developed as humanized or human antibodies and are far less immunogenic. The use of a fully humanized IgG1 mAb against TNF&#945; (adalimumab) triggered the development of ADA in patients with plaque psoriasis (<xref rid="B18" ref-type="bibr">18</xref>) and rheumatoid arthritis (<xref rid="B19" ref-type="bibr">19</xref>&#8211;<xref rid="B22" ref-type="bibr">22</xref>), indicating that ADA development to therapeutics can vary depending on factors like preexisting activation of the immune system and chronic inflammation.</p><p>Monoclonal antibodies constitute a large fraction of biotherapeutics and target a specific protein, usually to inhibit or modulate its function; in some cases, they may have a diagnostic role, or they may deliver a drug. The rest of protein therapeutics are primarily replacement therapies for proteins that are deficient owing to genetic or other reasons. Such protein therapeutics include coagulation factors, hormones, growth factors, and enzymes. Recently, fusion proteins are becoming an important class of biotherapeutics (<xref rid="T1" ref-type="table">Table 1</xref>). There are several examples of albumin fusion, Fc fusion, and antibody drug conjugates available in the market (<xref rid="B33" ref-type="bibr">33</xref>). The breadth and the complexity of protein therapeutics increase the potential for immune response generation. Protein therapeutic immunogenicity poses a great challenge in the field; and a better understanding of the risks, development, and mechanisms of ADA is needed to allow for strategies to reduce immunogenicity.</p><table-wrap id="T1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Reported ADA development for licensed therapeutics.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"><bold>Drug name</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Type</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Clinical use</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>ADA prevalence</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Citation</bold></th></tr></thead><tbody><tr><td valign="top" align="left" colspan="5" rowspan="1"><bold>Monoclonal antibodies</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Muromonab-CD3</td><td valign="top" align="left" rowspan="1" colspan="1">Murine against CD3</td><td valign="top" align="left" rowspan="1" colspan="1">Immunosuppression for the prevention of allograft rejection in transplants</td><td valign="top" align="center" rowspan="1" colspan="1">43&#8211;91%</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B14" ref-type="bibr">14</xref>&#8211;<xref rid="B17" ref-type="bibr">17</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Infliximab</td><td valign="top" align="left" rowspan="1" colspan="1">Chimeric human/mouse IgG1 against TNF&#945;</td><td valign="top" align="left" rowspan="1" colspan="1">Rheumatoid arthritis, inflammatory bowel disease, plaque psoriasis</td><td valign="top" align="center" rowspan="1" colspan="1">5.4&#8211;43.6%</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B21" ref-type="bibr">21</xref>, <xref rid="B23" ref-type="bibr">23</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Cetuximab</td><td valign="top" align="left" rowspan="1" colspan="1">Chimeric human/mouse IgG1 against EGFR</td><td valign="top" align="left" rowspan="1" colspan="1">Colorectal cancer, squamous cell carcinoma (head/neck)</td><td valign="top" align="center" rowspan="1" colspan="1">0.6&#8211;20.8%</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B24" ref-type="bibr">24</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Adalimumab</td><td valign="top" align="left" rowspan="1" colspan="1">Human IgG1 against TNF&#945;</td><td valign="top" align="left" rowspan="1" colspan="1">Plaque psoriasis, rheumatoid arthritis, Crohn's disease, spondyloarthritis, psoriatic arthritis</td><td valign="top" align="center" rowspan="1" colspan="1">17&#8211;49%</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B18" ref-type="bibr">18</xref>, <xref rid="B20" ref-type="bibr">20</xref>&#8211;<xref rid="B22" ref-type="bibr">22</xref>, <xref rid="B25" ref-type="bibr">25</xref>)</td></tr><tr><td valign="top" align="left" colspan="5" rowspan="1"><bold>Other drugs</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><sc>L</sc>-Asparaginase</td><td valign="top" align="left" rowspan="1" colspan="1">Enzyme</td><td valign="top" align="left" rowspan="1" colspan="1">Acute lymphoblastic leukemia in adult and children</td><td valign="top" align="center" rowspan="1" colspan="1">2% (PEG-Asp&#8211;neutralizing ADA;) 26% (<italic toggle="yes">Escherichia coli</italic>-Asp)</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B26" ref-type="bibr">26</xref>, <xref rid="B27" ref-type="bibr">27</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">FVIII</td><td valign="top" align="left" rowspan="1" colspan="1">Anti-hemorrhagic protein</td><td valign="top" align="left" rowspan="1" colspan="1">Hemophilia A/B</td><td valign="top" align="center" rowspan="1" colspan="1">3.6&#8211;33% (25&#8211;30% in those with severe hemophilia)</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B28" ref-type="bibr">28</xref>, <xref rid="B29" ref-type="bibr">29</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">IFN-&#946;</td><td valign="top" align="left" rowspan="1" colspan="1">Mammalian cytokine</td><td valign="top" align="left" rowspan="1" colspan="1">Multiple sclerosis</td><td valign="top" align="center" rowspan="1" colspan="1">2&#8211;53%</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B30" ref-type="bibr">30</xref>&#8211;<xref rid="B32" ref-type="bibr">32</xref>)</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">ADA, antidrug antibody; EGFR, epidermal growth factor receptor</italic>.</p></table-wrap-foot></table-wrap><sec><title>Generation and Mechanisms of Action of Antidrug Antibodies</title><p>Several factors contributing to the immunogenicity of biotherapeutics have been identified and in many cases eliminated to generate better drugs. For example, animal proteins have been for the most part phased out of the market, as these were very often associated with strong immune responses. Initially, many recombinant proteins were generated through bacterial systems (especially <italic toggle="yes">E. coli</italic>), which are effective and simple to use but lack the higher mechanisms for glycosylation and therefore are often immunogenic in humans. Mammalian expression systems are now commonly used for biotherapeutics to allow for glycosylation. However, even within mammalian species, glycosylation may differ contributing to the development of ADA. For example, cetuximab, a monoclonal antibody against epidermal growth factor receptor (EGFR) inhibitor (<xref rid="B24" ref-type="bibr">24</xref>, <xref rid="B34" ref-type="bibr">34</xref>, <xref rid="B35" ref-type="bibr">35</xref>) generated in a mouse myeloma cell line SP2/0 was associated with development of ADA owing to its glycosylation profile (<xref rid="B24" ref-type="bibr">24</xref>, <xref rid="B34" ref-type="bibr">34</xref>&#8211;<xref rid="B36" ref-type="bibr">36</xref>). Introduction of alternative mammalian cell lines [Chinese hamster ovary (CHO)] has greatly contributed to overcoming immunogenicity due to glycosylation patterns (<xref rid="B34" ref-type="bibr">34</xref>, <xref rid="B35" ref-type="bibr">35</xref>). <sc>l</sc>-Asparaginase, a highly immunogenic enzyme, is effective in its own native, <italic toggle="yes">E. coli</italic> derived form (<xref rid="B37" ref-type="bibr">37</xref>, <xref rid="B38" ref-type="bibr">38</xref>). However, allergic reactions due to multiple doses caused silent hypersensitivity that in turns generates ADA. Use of a pegylated form (<xref rid="B26" ref-type="bibr">26</xref>) or increasing the enzyme binding to erythrocytes (<xref rid="B39" ref-type="bibr">39</xref>) was able to reduce the development of ADA during multiple doses of <italic toggle="yes">E</italic>. <italic toggle="yes">coli</italic> asparaginase.</p><p>In patients receiving replacement therapy, a significant factor affecting their risk to ADA development is the levels of endogenous protein, with patients expressing no or very little protein being at a much higher risk, presumably owing to compromised central tolerance induction (<xref rid="B40" ref-type="bibr">40</xref>). Even a few amino acid sequence changes between the endogenous protein and the administered biotherapeutic may lead to an increased risk in immunogenicity. Substitution of just three amino acids in the recombinant activated factor VII (rFVIIa) (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B41" ref-type="bibr">41</xref>) was shown to significantly increase immunogenicity of the therapeutic protein. In addition, dosing (<xref rid="B42" ref-type="bibr">42</xref>), protein folding/aggregation, route of administration, storage conditions, and excipients may also affect the development of ADA (<xref rid="B43" ref-type="bibr">43</xref>, <xref rid="B44" ref-type="bibr">44</xref>). It has been proposed that even codon usage of the recombinant protein may affect protein conformation and modulate immunogenicity (<xref rid="B45" ref-type="bibr">45</xref>). The inhibitory activity of ADA can be mediated by several mechanisms. Development of anti-idiotypic antibodies against the therapeutic could lead to <italic toggle="yes">in vivo</italic> formation of immune complexes (ICs), which can diminish therapeutic efficacy by reducing the half-life of the therapeutic or engaging the complement cascade (<xref rid="B46" ref-type="bibr">46</xref>, <xref rid="B47" ref-type="bibr">47</xref>). Larger ICs are removed from circulation faster than smaller ICs owing to engagement of FcR on macrophages, reducing drug levels and requiring more frequent administration (<xref rid="B47" ref-type="bibr">47</xref>, <xref rid="B48" ref-type="bibr">48</xref>). Complement cascade activation (as seen with administration of therapeutic IFN-&#946; for multiple sclerosis) enhances inflammatory responses (<xref rid="B46" ref-type="bibr">46</xref>, <xref rid="B47" ref-type="bibr">47</xref>). Alternatively, generation of neutralizing antibodies (i.e., adalimumab and infliximab, anti-TNF&#945;, and monoclonal Abs) could directly block the action of the administered antibody or modulate its <italic toggle="yes">in vivo</italic> half-life (<xref rid="B18" ref-type="bibr">18</xref>, <xref rid="B25" ref-type="bibr">25</xref>, <xref rid="B49" ref-type="bibr">49</xref>, <xref rid="B50" ref-type="bibr">50</xref>). In rare cases, ADA generation may lead to anaphylactic shock and death (<xref rid="B51" ref-type="bibr">51</xref>).</p></sec><sec><title>Lymph Nodes: Primary Sites for the Development of Immune Responses Against Pathogens</title><sec><title>Structure</title><p>Lymph node positioning along lymphatic vessels enables the efficient draining and detection of pathogens and immunogens (<xref ref-type="fig" rid="F1">Figure 1</xref>). The number of human LNs varies depending on age and disease status (<xref rid="B52" ref-type="bibr">52</xref>&#8211;<xref rid="B56" ref-type="bibr">56</xref>). The LN architecture is characterized by well-organized, distinct anatomical areas: cortex, paracortex, follicles, germinal centers (GCs), high endothelial venules (HEVs), medulla, and fibroblastic reticular cells (FRCs) (<xref rid="B57" ref-type="bibr">57</xref>, <xref rid="B58" ref-type="bibr">58</xref>) (<xref ref-type="fig" rid="F1">Figure 1</xref>). The formation of distinct LN areas contributes to the compartmentalization of cellular and molecular mechanisms involved in the generation of antigen-specific humoral responses. This compartmentalization further contributes to the control of relevant immune interactions and reduction of unwanted B cell responses. The cortex consists of many lymphocytes, mainly naive B cells (sIgD+IgM+) packed into primary follicles (absence of GC) or secondary follicles that are characterized by the formation of GC (<xref rid="B58" ref-type="bibr">58</xref>, <xref rid="B59" ref-type="bibr">59</xref>). GCs are the areas where B cells proliferate in response to T cell-dependent antigen and create memory cells and plasma cells (<xref rid="B57" ref-type="bibr">57</xref>). Two major GC areas have been characterized, dark zone (DZ) and light zone (LZ), with different cellularities and roles for the development of B cell responses (<xref rid="B60" ref-type="bibr">60</xref>, <xref rid="B61" ref-type="bibr">61</xref>). The deeper cortex, also known as the paracortex, contains HEVs, which are specialized blood vessels that allow circulating lymphocytes, such as T cells, and innate immunity cells to directly enter the LN (<xref rid="B58" ref-type="bibr">58</xref>). The local interaction between T and dendritic cell (DC) subsets initiates a cascade of immune reactions critical to the formation of mature GCs (<xref rid="B57" ref-type="bibr">57</xref>). The medulla, located on the efferent side where the lymph drains out of the LN, contains blood vessels and medullary cords enriched in B cells, macrophages, and plasma cells (<xref ref-type="fig" rid="F1">Figure 1</xref>). Finally, the backbone of the LN architecture is the FRCs. The FRCs form a network that allow DCs and T cells to travel throughout the LN (<xref rid="B62" ref-type="bibr">62</xref>).</p><fig id="F1" position="float" orientation="portrait"><label>Figure 1</label><caption><p>The lymph node structure/organization is shown. A zoomed T cell/follicular area with the major cell types involved in the development of antibody responses is shown. The presence of therapeutic within the lymph node can initiate a cascade of immune reactions ultimately leading to T cell-dependent germinal center (GC) activity and the generation of plasma cells and memory B cells that can produce antibodies. The cascade begins with (1) dendritic cells that present the therapeutic interaction with CD4 T cells resulting in their activation and differentiation; (2) activated CD4 T cells begin interacting with B cells, ultimately leading to further differentiation of both cell types and therefore trafficking into follicles/GCs; (3) within the GC, follicular CD4 T cells interact with GC B cells and follicular dendritic cell (FDC); (4) helping B cells promotes their maturation to memory and plasma cells.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fimmu-11-00791-g0001.jpg"/></fig></sec><sec><title>Major Cell Populations</title><p>T cell zone (paracortex) is populated with innate immunity cells (DC, monocytes, macrophages, and granulocytes), adaptive immunity cells (CD4 and CD8), and stromal cells (FRCs). Subcapsular sinus macrophages is the first lymph node population encountering pathogens from the lymph (<xref rid="B63" ref-type="bibr">63</xref>) that controls the pathogen dissemination and inflammation and affects B cell responses to subsequent infections (<xref rid="B64" ref-type="bibr">64</xref>). These cells can trigger responses to lipid antigens, a mechanism mediated by activation of LN invariant natural killer cells (iNKTs) (<xref rid="B65" ref-type="bibr">65</xref>). Recirculating monocytes can traffic to LNs and either keep their classical status (<xref rid="B66" ref-type="bibr">66</xref>) or further differentiate to macrophages or DCs and initiate adaptive responses (<xref rid="B67" ref-type="bibr">67</xref>, <xref rid="B68" ref-type="bibr">68</xref>). T cell zone macrophages can also function as scavengers for apoptotic cells (<xref rid="B69" ref-type="bibr">69</xref>). DC and monocyte in LNs are main producers of IL-6, an important cytokine for the differentiation development of Tfh cells (<xref rid="B70" ref-type="bibr">70</xref>, <xref rid="B71" ref-type="bibr">71</xref>). FRCs provide a vital network for (i) recruitment of naive T cells and DCs through CCL21 and CCL19, the CCR7 ligands (<xref rid="B72" ref-type="bibr">72</xref>), a major chemokine receptor mediating tissue trafficking of several cell types (<xref rid="B73" ref-type="bibr">73</xref>, <xref rid="B74" ref-type="bibr">74</xref>); (ii) T cell survival through IL-7, a survival factor particularly for naive T cells (<xref rid="B75" ref-type="bibr">75</xref>, <xref rid="B76" ref-type="bibr">76</xref>); and (iii) trafficking of CD4 T cells toward the GC (<xref rid="B62" ref-type="bibr">62</xref>). When an antigen is present, major rearrangements take place within this area. Studies using mouse models have shown that the presence of antigen triggers the activation and repositioning of DC cells (<xref rid="B77" ref-type="bibr">77</xref>, <xref rid="B78" ref-type="bibr">78</xref>), which have an important effect on CD4 T cell activation as well as the initiation of CD4 T and B cell interaction. B cells will follow a CCR7 gradient toward the follicle/T-zone (T&#8211;B) boundary where they could bind to multiple helper CD4 T cells at once, whereas T cells would only bind one at a time (<xref rid="B79" ref-type="bibr">79</xref>). The interaction of CD4 T and B cells in the T cell zone will activate a cascade of immune dynamics associated with major changes in differentiation status (phenotypes, transcriptome profile, and trafficking) (<xref rid="B80" ref-type="bibr">80</xref>) of both CD4 and B cells, ultimately enabling their trafficking into the GC area. In fact, the interaction between CD4, B, and antigen-presenting cells (APCs) in the T cell zone and T&#8211;B borders is required for optimal differentiation of CD4 T cells to Tfh cells (<xref rid="B81" ref-type="bibr">81</xref>, <xref rid="B82" ref-type="bibr">82</xref>). These early interactions are also critical to the further development of B cell responses (<xref rid="B83" ref-type="bibr">83</xref>, <xref rid="B84" ref-type="bibr">84</xref>).</p></sec></sec></sec><sec id="s3"><title>Germinal Center: The Laboratory for the Development of B Cell Responses</title><p>The role of the Tfh cells is to help create high-affinity memory B and plasma cells (<xref rid="B85" ref-type="bibr">85</xref>); thus, this subset of CD4 T cells is crucial in the immune response. GCs, the structures found in mature, secondary follicles (<xref rid="B59" ref-type="bibr">59</xref>), are populated with activated B cells, follicular DCs (FDCs), Tfh cells, and macrophages (tingible body macrophages) (<xref rid="B59" ref-type="bibr">59</xref>). Upon antigen stimulation, naive B cells traffic to the T&#8211;B border following a CCR7 gradient (<xref rid="B79" ref-type="bibr">79</xref>). Further interaction with CD4 T cells and receipt of co-stimulatory signals (<xref rid="B86" ref-type="bibr">86</xref>) trigger a rigorous proliferation of B cells and the formation of a tight cluster within the follicle, which becomes the GC. Within the GC, the B cells undergo somatic hypermutation, affinity maturation, class switch recombination, and plasma/memory B cell production (<xref rid="B87" ref-type="bibr">87</xref>&#8211;<xref rid="B89" ref-type="bibr">89</xref>). Formation of GC is mediated by help from FDCs and the function of G-protein-coupled receptors (GPCR) like S1PR2 and P2RY8 (<xref rid="B59" ref-type="bibr">59</xref>, <xref rid="B90" ref-type="bibr">90</xref>, <xref rid="B91" ref-type="bibr">91</xref>). In primary follicles, FDCs help B cells form a follicle (<xref rid="B92" ref-type="bibr">92</xref>), whereas in secondary follicles, FDCs support GC B cell survival (<xref rid="B93" ref-type="bibr">93</xref>&#8211;<xref rid="B97" ref-type="bibr">97</xref>). B cell survival was impaired when FDCs were exposed to HIV-1 (<xref rid="B98" ref-type="bibr">98</xref>), smaller GCs, formed and lower antibody titers were obtained when FDC activation was blocked through TLR4 (<xref rid="B99" ref-type="bibr">99</xref>). FDCs modulate antigen availability by cycling the antigens between the FDC surface and other endosomal compartments (<xref rid="B100" ref-type="bibr">100</xref>) or accumulating ICs bound to Fc receptors on their cell surface (<xref rid="B100" ref-type="bibr">100</xref>), a process critical to the affinity maturation of B cells (<xref rid="B101" ref-type="bibr">101</xref>, <xref rid="B102" ref-type="bibr">102</xref>). Tfh cells are a subset of CD4 T cells that are specialized to help B cells. They are located inside B cell follicles of secondary lymphoid organs and are responsible for activation, isotype switching, affinity maturation, and differentiation of B cells (<xref rid="B103" ref-type="bibr">103</xref>&#8211;<xref rid="B105" ref-type="bibr">105</xref>). Tfh cells express a unique phenotype and transcriptome signature (<xref rid="B106" ref-type="bibr">106</xref>&#8211;<xref rid="B109" ref-type="bibr">109</xref>). A mutual regulation through modulation of Bcl-6 between Tfh and GC B cells has been proposed (<xref rid="B110" ref-type="bibr">110</xref>&#8211;<xref rid="B112" ref-type="bibr">112</xref>). Tfh cells produce cytokines like IL-21 and IL-4, which are important for the GC B cell dynamics (<xref rid="B105" ref-type="bibr">105</xref>, <xref rid="B113" ref-type="bibr">113</xref>&#8211;<xref rid="B115" ref-type="bibr">115</xref>) and maintenance of Tfh cells. Two distinct GC areas have been identified; the DZ, where B cell proliferation and somatic hypermutation occurs, and the LZ, where B cells interact with Tfh cells and FDCs (<xref rid="B60" ref-type="bibr">60</xref>, <xref rid="B116" ref-type="bibr">116</xref>). Expression of the chemokine receptor CXCR4, which is highly expressed on Tfh and GC B cells (<xref rid="B117" ref-type="bibr">117</xref>, <xref rid="B118" ref-type="bibr">118</xref>), and local production of its ligand CXCL12 (SDF-1) in DZ by CXCL12-expressing reticular cells (CRC) (<xref rid="B119" ref-type="bibr">119</xref>, <xref rid="B120" ref-type="bibr">120</xref>) play a critical role for the organization of DZ and LZ (<xref rid="B116" ref-type="bibr">116</xref>, <xref rid="B121" ref-type="bibr">121</xref>, <xref rid="B122" ref-type="bibr">122</xref>). LZ is less compact and more diverse than is DZ. B cells continuously move between the DZ and LZ, helping in the further differentiation and affinity maturation of GC B cells (<xref rid="B123" ref-type="bibr">123</xref>&#8211;<xref rid="B126" ref-type="bibr">126</xref>). Within the LZ, B cells continuously interact with Tfh, FDC, and antigen, interactions that dictate their survival and clonal selection (<xref rid="B84" ref-type="bibr">84</xref>, <xref rid="B127" ref-type="bibr">127</xref>&#8211;<xref rid="B129" ref-type="bibr">129</xref>).</p><sec><title>Germinal Center Reactivity Against Therapeutics</title><p>Several studies have investigated GC dynamics after drug administration. Understanding how the LN and GC react to therapeutics (antibodies, recombinant proteins, cytokines, vaccines, enzymes, etc.) is important to reduce/eliminate ADA development. ADA can be generated by T cell-dependent (Td) and T cell-independent (Ti) pathways (<xref rid="B130" ref-type="bibr">130</xref>&#8211;<xref rid="B132" ref-type="bibr">132</xref>). The Td pathway involves an antigen-activated T cell that then stimulates B cell activation and differentiation to plasma cells. Neutralizing IgG4 ADA against FVIII (<xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B133" ref-type="bibr">133</xref>) was triggered by a Th2 CD4 T cell response (<xref rid="B134" ref-type="bibr">134</xref>), whereas initiation of Th1 responses was found to induce IgG1 and IgG2 ADA against FVIII when patients were on immunosuppressive therapy (<xref rid="B134" ref-type="bibr">134</xref>), which may sometimes be non-neutralizing (<xref rid="B133" ref-type="bibr">133</xref>, <xref rid="B134" ref-type="bibr">134</xref>). Administration of IFN-&#946; was found to induce either non-neutralizing and transient neutralizing ADA, mainly of low titers and affinity IgG1 and IgG3 subclasses, or persistent neutralizing ADA, which had mostly IgG2 and IgG4 antibodies (<xref rid="B135" ref-type="bibr">135</xref>). ADA binding affinity was positively correlated with IgG4 production and neutralizing ADA titers but negatively correlated with IgG3 production. Similarly, generation of high-affinity antibodies to biopharmaceuticals is CD4 T cell dependent (<xref rid="B136" ref-type="bibr">136</xref>, <xref rid="B137" ref-type="bibr">137</xref>). In fact several studies have shown the development of neutralizing antibodies ADA (<xref rid="B138" ref-type="bibr">138</xref>&#8211;<xref rid="B142" ref-type="bibr">142</xref>) mainly of IgG4 subtype (<xref rid="B143" ref-type="bibr">143</xref>). Similar polyclonal IgG1 responses consisting of neutralizing and non-neutralizing specificities have also been detected in response to natalizumab (NZM) administration in multiple sclerosis patients. Neutralizing antibodies in these patients carry a higher load of somatic mutations in the complementary determining regions (CDRs) and have a higher affinity than have non-neutralizing, binding antibody specificities, which is consistent with LN-specific antigen-driven selection (<xref rid="B144" ref-type="bibr">144</xref>).</p><p>These considerations indicate that alternative cytokine milieu and initial programing of CD4 T cells in the LN can affect the outcome of the GC B cell responses to a given therapeutic in a way that parallels the LN-associated changes seen in vaccine-specific or pathogen-associated antibody production. The Ti pathway is triggered when the B cell is activated directly by the antigen. In general, polyvalent antigens, such as an aggregated biologic (<xref rid="B145" ref-type="bibr">145</xref>, <xref rid="B146" ref-type="bibr">146</xref>), are more likely to induce Ti-B cell responses (<xref rid="B147" ref-type="bibr">147</xref>, <xref rid="B148" ref-type="bibr">148</xref>). Ti responses lead to IgM or low affinity IgG ADA owing to lack of T cell help (<xref rid="B130" ref-type="bibr">130</xref>). Because most ADAs are IgG, the possible role of complement activation by ADA needs further investigation (<xref rid="B130" ref-type="bibr">130</xref>). Neutralizing antibodies, particularly the broad neutralizing antibodies (bNABs), are characterized by high levels of somatic mutations (<xref rid="B149" ref-type="bibr">149</xref>) and are indicative of GC maturation. The mechanisms leading to such maturation process in the GC are not well-understood. Presumably, antigen concentration within LN/GC and the co-evolution of Tfh and GC B cells (selection of TCR and BCR clones) are major biological factors affecting this process. Studies using mouse models have shown that the quality of Tfh help to GC B cell is an important biological factor for the development of high-affinity antibodies (<xref rid="B127" ref-type="bibr">127</xref>, <xref rid="B129" ref-type="bibr">129</xref>, <xref rid="B150" ref-type="bibr">150</xref>). Specifically, Tfh helps regulate the metabolic programming of LZ B cells that support their proliferation in DZ (<xref rid="B129" ref-type="bibr">129</xref>). Furthermore, this helps prolong the duration of B cell cycle in the DZ, a process associated with the generation of high-affinity GC B cells (<xref rid="B151" ref-type="bibr">151</xref>). Shuttling/binding of antigen to FDC (<xref rid="B152" ref-type="bibr">152</xref>) as well as the amount of antigen presented to Tfh by GC B cells (<xref rid="B150" ref-type="bibr">150</xref>) can have a significant impact on the development of high-affinity B cell responses. Dynamics and factors in the follicular, non-GC area can also affect the maturation of B cell responses. High-affinity B cell clones can be selected during early interaction between CD4 T and B cells at the T&#8211;B cell border (<xref rid="B84" ref-type="bibr">84</xref>), whereas class switch recombination can be started outside GC (<xref rid="B153" ref-type="bibr">153</xref>). Furthermore, recently identified populations like the CD25+FoxP3+ T follicular IL-10-producing cells (<xref rid="B154" ref-type="bibr">154</xref>) and Tbet+ B cells, mainly localized around the GC (<xref rid="B155" ref-type="bibr">155</xref>), could be important regulators for the development of neutralizing antibodies. Host genetics are also relevant. The presentation of MHC class II-restricted drug-specific peptides on CD4+ T cells can further contribute to the emergence and maintenance of polyclonal drug-specific B cell responses in lymphoid localities (<xref rid="B144" ref-type="bibr">144</xref>). Conversely, elimination of specific drug-associated T cell epitopes in mice treated with recombinant immunotoxins curtails the development of high-affinity antidrug IgG responses in primary as well as anamnestic responses (<xref rid="B156" ref-type="bibr">156</xref>). Taken together, these findings suggest that at least for some types of biologic pharmaceuticals, T-dependent pathways in LNs are central in the induction of neutralizing ADAs. Therefore, understanding in more detail the nature, trafficking/distribution of each biopharmaceutical into LN and its availability/sustainability on FDCs is warranted, as these are factors could direct the cellular and molecular mechanisms immobilized in the LN, which lead to the development of specific types of antibody responses, especially in the absence of adjuvants, which trigger innate immunity.</p></sec></sec><sec sec-type="conclusions" id="s4"><title>Conclusions</title><p>The cellular and molecular mechanisms governing the development of ADA responses in humans are not well-understood. This is a highly coordinated process taking place in secondary lymphoid organs where the nature of the &#8220;antigen,&#8221; tissue structure, and spatial positioning of relevant cell populations, particularly in the follicular/GC area, play a critical role for the host&#8211;therapeutic interplay leading to the differentiation of adaptive immune cells to enable the generation of antibody-secreting B cells. Today, the link between ADA and changes in LN function is still not well-studied. Major aspects related to ADA development that need further investigation include the following:</p><list list-type="order"><list-item><p>The trafficking and sustainability of a particular therapeutic in the LN areas, particularly the GC. Formulation for the <italic toggle="yes">in vivo</italic> delivery of an immunogen could significantly change its dynamics in the GCs with major impact on the B cell response development (<xref rid="B157" ref-type="bibr">157</xref>, <xref rid="B158" ref-type="bibr">158</xref>).</p></list-item><list-item><p>The activation of specific innate immunity cells and the concomitant changes in the local cytokine/chemokine milieu are factors regulating the degree of CD4 T cell help for the B cell responses (<xref rid="B78" ref-type="bibr">78</xref>).</p></list-item><list-item><p>The possible association between ADA titer and affinity maturation and particular GC dynamics (i.e., magnitude of Tfh cell responses and expansion of particular Tfh subsets).</p></list-item><list-item><p>The possible role of preexisting immune activation and inflammation within the lymphoid organs.</p></list-item></list><p>Of particular interest is the investigation of ADA development in aging where the GC dynamics are different compared with those in young individuals (<xref rid="B159" ref-type="bibr">159</xref>&#8211;<xref rid="B161" ref-type="bibr">161</xref>) as well as in chronic inflammatory diseases like HIV and autoimmunity. For example, altered antibody responses are expected in HIV-infected individuals where chronic infection is associated with LN inflammation, architecture damage (fibrosis), and dramatic changes to GC dynamics (<xref rid="B100" ref-type="bibr">100</xref>, <xref rid="B155" ref-type="bibr">155</xref>, <xref rid="B162" ref-type="bibr">162</xref>, <xref rid="B163" ref-type="bibr">163</xref>). Such LN changes could have a major impact in the ADA development to a specific therapeutic. Despite the limited predictive value for the drug immunogenicity in humans based on non-human primate (NHP) studies (<xref rid="B164" ref-type="bibr">164</xref>), NHP represents the only model for testing antibody development under such conditions. However, we need to keep in mind that compared with that in humans, ADA in NHP is mainly directed against the Fc region of the monoclonal antibody, causing loss of efficacy and adverse effects. Supplemental to human studies, investigation of therapeutic immunogenicity, when it occurs, in NHPs could lead to identification of particular cell types, molecules, and molecular pathways driving the responses to a particular therapeutic. The wide range of titers, subtypes, and function of ADA induced by different therapeutics argues for the need for identification of &#8220;LN molecular/cellular signatures&#8221; specific to certain therapeutic, which could lead to targets for &#8220;individualized&#8221; <italic toggle="yes">in vivo</italic> manipulation of ADA development.</p></sec><sec id="s5"><title>Author Contributions</title><p>All authors listed have made a substantial, direct and intellectual contribution to the work, and approved it for publication.</p></sec><sec id="s6"><title>Conflict of Interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The handling editor declared a shared affiliation, though no other collaboration, with one of the authors AA at time of review.</p></sec></body><back><fn-group><fn fn-type="financial-disclosure"><p><bold>Funding.</bold> This research was supported by the Intramural Research Program of the Vaccine Research Center, NIAID, National Institutes of Health; and a CAVD grant (#OP1032325) from the Bill and Melinda Gates Foundation.</p></fn></fn-group><ref-list><title>References</title><ref id="B1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pratt</surname><given-names>KP</given-names></name></person-group>. <article-title>Anti-drug antibodies: emerging approaches to predict, reduce or reverse biotherapeutic immunogenicity</article-title>. <source>Antibodies</source>. (<year>2018</year>) <volume>31</volume>:<fpage>7</fpage>. <pub-id pub-id-type="doi">10.3390/antib7020019</pub-id><pub-id pub-id-type="pmid">31544871</pub-id><pub-id pub-id-type="pmcid">PMC6698869</pub-id></mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuka</surname><given-names>M</given-names></name><name name-style="western"><surname>Iannacone</surname><given-names>M</given-names></name></person-group>. <article-title>Viral subversion of B cell responses within secondary lymphoid organs</article-title>. <source>Nat Rev Immunol</source>. (<year>2018</year>) <volume>18</volume>:<fpage>255</fpage>&#8211;<lpage>65</lpage>. <pub-id pub-id-type="doi">10.1038/nri.2017.133</pub-id><pub-id pub-id-type="pmid">29249807</pub-id><pub-id pub-id-type="pmcid">PMC7237239</pub-id></mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bar-Ephraim</surname><given-names>YE</given-names></name><name name-style="western"><surname>Mebius</surname><given-names>RE</given-names></name></person-group>. <article-title>Innate lymphoid cells in secondary lymphoid organs</article-title>. <source>Immunol Rev</source>. (<year>2016</year>) <volume>271</volume>:<fpage>185</fpage>&#8211;<lpage>99</lpage>. <pub-id pub-id-type="doi">10.1111/imr.12407</pub-id><pub-id pub-id-type="pmid">27088915</pub-id></mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Magrone</surname><given-names>T</given-names></name><name name-style="western"><surname>Jirillo</surname><given-names>E</given-names></name></person-group>. <article-title>Development and organization of the secondary and tertiary lymphoid organs: influence of microbial and food antigens</article-title>. <source>Endocr Metab Immune Disord Drug Targets</source>. (<year>2019</year>) <volume>19</volume>:<fpage>128</fpage>&#8211;<lpage>35</lpage>. <pub-id pub-id-type="doi">10.2174/1871530319666181128160411</pub-id><pub-id pub-id-type="pmid">30488802</pub-id></mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Onder</surname><given-names>L</given-names></name><name name-style="western"><surname>Morbe</surname><given-names>U</given-names></name><name name-style="western"><surname>Pikor</surname><given-names>N</given-names></name><name name-style="western"><surname>Novkovic</surname><given-names>M</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>HW</given-names></name><name name-style="western"><surname>Hehlgans</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Lymphatic endothelial cells control initiation of lymph node organogenesis</article-title>. <source>Immunity</source>. (<year>2017</year>) <volume>47</volume>:<fpage>80</fpage>&#8211;<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1016/j.immuni.2017.05.008</pub-id><pub-id pub-id-type="pmid">28709801</pub-id></mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baker</surname><given-names>MP</given-names></name><name name-style="western"><surname>Reynolds</surname><given-names>HM</given-names></name><name name-style="western"><surname>Lumicisi</surname><given-names>B</given-names></name><name name-style="western"><surname>Bryson</surname><given-names>CJ</given-names></name></person-group>. <article-title>Immunogenicity of protein therapeutics: the key causes, consequences and challenges</article-title>. <source>Self Nonself</source> . (<year>2010</year>) <volume>1</volume>:<fpage>314</fpage>&#8211;<lpage>22</lpage>. <pub-id pub-id-type="doi">10.4161/self.1.4.13904</pub-id><pub-id pub-id-type="pmid">21487506</pub-id><pub-id pub-id-type="pmcid">PMC3062386</pub-id></mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dimopoulos</surname><given-names>Y</given-names></name><name name-style="western"><surname>Moysi</surname><given-names>E</given-names></name><name name-style="western"><surname>Petrovas</surname><given-names>C</given-names></name></person-group>. <article-title>The lymph node in HIV pathogenesis</article-title>. <source>Curr HIV/AIDS Rep</source>. (<year>2017</year>) <volume>14</volume>:<fpage>133</fpage>&#8211;<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1007/s11904-017-0359-7</pub-id><pub-id pub-id-type="pmid">28685417</pub-id></mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Denton</surname><given-names>AE</given-names></name><name name-style="western"><surname>Linterman</surname><given-names>MA</given-names></name></person-group>. <article-title>Stromal networking: cellular connections in the germinal centre</article-title>. <source>Curr Opin Immunol</source>. (<year>2017</year>) <volume>45</volume>:<fpage>103</fpage>&#8211;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1016/j.coi.2017.03.001</pub-id><pub-id pub-id-type="pmid">28319729</pub-id></mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ruddle</surname><given-names>NH</given-names></name><name name-style="western"><surname>Akirav</surname><given-names>EM</given-names></name></person-group>. <article-title>Secondary lymphoid organs: responding to genetic and environmental cues in ontogeny and the immune response</article-title>. <source>J Immunol</source>. (<year>2009</year>) <volume>183</volume>:<fpage>2205</fpage>&#8211;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.0804324</pub-id><pub-id pub-id-type="pmid">19661265</pub-id><pub-id pub-id-type="pmcid">PMC2766168</pub-id></mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hansen</surname><given-names>KC</given-names></name><name name-style="western"><surname>D'Alessandro</surname><given-names>A</given-names></name><name name-style="western"><surname>Clement</surname><given-names>CC</given-names></name><name name-style="western"><surname>Santambrogio</surname><given-names>L</given-names></name></person-group>. <article-title>Lymph formation, composition and circulation: a proteomics perspective</article-title>. <source>Int Immunol</source>. (<year>2015</year>) <volume>27</volume>:<fpage>219</fpage>&#8211;<lpage>27</lpage>. <pub-id pub-id-type="doi">10.1093/intimm/dxv012</pub-id><pub-id pub-id-type="pmid">25788586</pub-id></mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pape</surname><given-names>KA</given-names></name><name name-style="western"><surname>Catron</surname><given-names>DM</given-names></name><name name-style="western"><surname>Itano</surname><given-names>AA</given-names></name><name name-style="western"><surname>Jenkins</surname><given-names>MK</given-names></name></person-group>. <article-title>The humoral immune response is initiated in lymph nodes by B cells that acquire soluble antigen directly in the follicles</article-title>. <source>Immunity</source>. (<year>2007</year>) <volume>26</volume>:<fpage>491</fpage>&#8211;<lpage>502</lpage>. <pub-id pub-id-type="doi">10.1016/j.immuni.2007.02.011</pub-id><pub-id pub-id-type="pmid">17379546</pub-id></mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gatto</surname><given-names>D</given-names></name><name name-style="western"><surname>Brink</surname><given-names>R</given-names></name></person-group>. <article-title>The germinal center reaction</article-title>. <source>J Allergy Clin Immunol</source>. (<year>2010</year>) <volume>126</volume>:<fpage>898</fpage>&#8211;<lpage>907</lpage>. <pub-id pub-id-type="doi">10.1016/j.jaci.2010.09.007</pub-id><pub-id pub-id-type="pmid">21050940</pub-id></mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leader</surname><given-names>B</given-names></name><name name-style="western"><surname>Baca</surname><given-names>QJ</given-names></name><name name-style="western"><surname>Golan</surname><given-names>DE</given-names></name></person-group>. <article-title>Protein therapeutics: a summary and pharmacological classification</article-title>. <source>Nat Rev Drug Discov</source>. (<year>2008</year>) <volume>7</volume>:<fpage>21</fpage>&#8211;<lpage>39</lpage>. <pub-id pub-id-type="doi">10.1038/nrd2399</pub-id><pub-id pub-id-type="pmid">18097458</pub-id></mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sgro</surname><given-names>C</given-names></name></person-group>. <article-title>Side-effects of a monoclonal antibody, muromonab CD3/orthoclone OKT3: bibliographic review</article-title>. <source>Toxicology</source>. (<year>1995</year>) <volume>105</volume>:<fpage>23</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/0300-483X(95)03123-W</pub-id><pub-id pub-id-type="pmid">8638282</pub-id></mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reichert</surname><given-names>JM</given-names></name></person-group>. <article-title>Marketed therapeutic antibodies compendium</article-title>. <source>MAbs</source>. (<year>2012</year>) <volume>4</volume>:<fpage>413</fpage>&#8211;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.4161/mabs.19931</pub-id><pub-id pub-id-type="pmid">22531442</pub-id><pub-id pub-id-type="pmcid">PMC3355480</pub-id></mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Niaudet</surname><given-names>P</given-names></name><name name-style="western"><surname>Jean</surname><given-names>G</given-names></name><name name-style="western"><surname>Broyer</surname><given-names>M</given-names></name><name name-style="western"><surname>Chatenoud</surname><given-names>L</given-names></name></person-group>. <article-title>Anti-OKT3 response following prophylactic treatment in paediatric kidney transplant recipients</article-title>. <source>Pediatr Nephrol</source>. (<year>1993</year>) <volume>7</volume>:<fpage>263</fpage>&#8211;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1007/BF00853215</pub-id><pub-id pub-id-type="pmid">8518095</pub-id></mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thistlethwaite</surname><given-names>JR</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Stuart</surname><given-names>JK</given-names></name><name name-style="western"><surname>Mayes</surname><given-names>JT</given-names></name><name name-style="western"><surname>Gaber</surname><given-names>AO</given-names></name><name name-style="western"><surname>Woodle</surname><given-names>S</given-names></name><name name-style="western"><surname>Buckingham</surname><given-names>MR</given-names></name><etal/></person-group>. <article-title>Complications and monitoring of OKT3 therapy</article-title>. <source>Am J Kidney Dis</source>. (<year>1988</year>) <volume>11</volume>:<fpage>112</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/S0272-6386(88)80192-6</pub-id><pub-id pub-id-type="pmid">3277401</pub-id></mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Menting</surname><given-names>SP</given-names></name><name name-style="western"><surname>van Lumig</surname><given-names>PP</given-names></name><name name-style="western"><surname>de Vries</surname><given-names>AC</given-names></name><name name-style="western"><surname>van den Reek</surname><given-names>JM</given-names></name><name name-style="western"><surname>van der Kleij</surname><given-names>D</given-names></name><name name-style="western"><surname>de Jong</surname><given-names>EM</given-names></name><etal/></person-group>. <article-title>Extent and consequences of antibody formation against adalimumab in patients with psoriasis: one-year follow-up</article-title>. <source>JAMA Dermatol</source>. (<year>2014</year>) <volume>150</volume>:<fpage>130</fpage>&#8211;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1001/jamadermatol.2013.8347</pub-id><pub-id pub-id-type="pmid">24352354</pub-id></mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Radstake</surname><given-names>TR</given-names></name><name name-style="western"><surname>Svenson</surname><given-names>M</given-names></name><name name-style="western"><surname>Eijsbouts</surname><given-names>AM</given-names></name><name name-style="western"><surname>van den Hoogen</surname><given-names>FH</given-names></name><name name-style="western"><surname>Enevld</surname><given-names>C</given-names></name><name name-style="western"><surname>van Riel</surname><given-names>PL</given-names></name><etal/></person-group>. <article-title>Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis</article-title>. <source>Ann Rheum Dis</source>. (<year>2009</year>) <volume>68</volume>:<fpage>1739</fpage>&#8211;<lpage>45</lpage>. <pub-id pub-id-type="doi">10.1136/ard.2008.092833</pub-id><pub-id pub-id-type="pmid">19019895</pub-id></mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bartelds</surname><given-names>GM</given-names></name><name name-style="western"><surname>Krieckaert</surname><given-names>CL</given-names></name><name name-style="western"><surname>Nurmohamed</surname><given-names>MT</given-names></name><name name-style="western"><surname>van Schouwenburg</surname><given-names>PA</given-names></name><name name-style="western"><surname>Lems</surname><given-names>WF</given-names></name><name name-style="western"><surname>Twisk</surname><given-names>JW</given-names></name><etal/></person-group>. <article-title>Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up</article-title>. <source>JAMA</source>. (<year>2011</year>) <volume>305</volume>:<fpage>1460</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1001/jama.2011.406</pub-id><pub-id pub-id-type="pmid">21486979</pub-id></mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moots</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Xavier</surname><given-names>RM</given-names></name><name name-style="western"><surname>Mok</surname><given-names>CC</given-names></name><name name-style="western"><surname>Rahman</surname><given-names>MU</given-names></name><name name-style="western"><surname>Tsai</surname><given-names>WC</given-names></name><name name-style="western"><surname>Al-Maini</surname><given-names>MH</given-names></name><etal/></person-group><article-title>The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: results from a multinational, real-world clinical practice, non-interventional study</article-title>. <source>PLoS ONE</source>. (<year>2017</year>) <volume>12</volume>:<fpage>e0175207</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0175207</pub-id><pub-id pub-id-type="pmid">28448562</pub-id><pub-id pub-id-type="pmcid">PMC5407581</pub-id></mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bartelds</surname><given-names>GM</given-names></name><name name-style="western"><surname>Wijbrandts</surname><given-names>CA</given-names></name><name name-style="western"><surname>Nurmohamed</surname><given-names>MT</given-names></name><name name-style="western"><surname>Stapel</surname><given-names>S</given-names></name><name name-style="western"><surname>Lems</surname><given-names>WF</given-names></name><name name-style="western"><surname>Aarden</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis</article-title>. <source>Ann Rheum Dis</source>. (<year>2007</year>) <volume>66</volume>:<fpage>921</fpage>&#8211;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1136/ard.2006.065615</pub-id><pub-id pub-id-type="pmid">17301106</pub-id><pub-id pub-id-type="pmcid">PMC1955110</pub-id></mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hsu</surname><given-names>L</given-names></name><name name-style="western"><surname>Armstrong</surname><given-names>AW</given-names></name></person-group>. <article-title>Anti-drug antibodies in psoriasis: a critical evaluation of clinical significance and impact on treatment response</article-title>. <source>Expert Rev Clin Immunol</source>. (<year>2013</year>) <volume>9</volume>:<fpage>949</fpage>&#8211;<lpage>58</lpage>. <pub-id pub-id-type="doi">10.1586/1744666X.2013.836060</pub-id><pub-id pub-id-type="pmid">24128157</pub-id></mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chung</surname><given-names>CH</given-names></name><name name-style="western"><surname>Mirakhur</surname><given-names>B</given-names></name><name name-style="western"><surname>Chan</surname><given-names>E</given-names></name><name name-style="western"><surname>Le</surname><given-names>QT</given-names></name><name name-style="western"><surname>Berlin</surname><given-names>J</given-names></name><name name-style="western"><surname>Morse</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose</article-title>. <source>N Engl J Med</source>. (<year>2008</year>) <volume>358</volume>:<fpage>1109</fpage>&#8211;<lpage>17</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa074943</pub-id><pub-id pub-id-type="pmid">18337601</pub-id><pub-id pub-id-type="pmcid">PMC2361129</pub-id></mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mok</surname><given-names>CC</given-names></name><name name-style="western"><surname>van der Kleij</surname><given-names>D</given-names></name><name name-style="western"><surname>Wolbink</surname><given-names>GJ</given-names></name></person-group>. <article-title>Drug levels, anti-drug antibodies, and clinical efficacy of the anti-TNFalpha biologics in rheumatic diseases</article-title>. <source>Clin Rheumatol</source>. (<year>2013</year>) <volume>32</volume>:<fpage>1429</fpage>&#8211;<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1007/s10067-013-2336-x</pub-id><pub-id pub-id-type="pmid">23887439</pub-id></mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Avramis</surname><given-names>VI</given-names></name><name name-style="western"><surname>Sencer</surname><given-names>S</given-names></name><name name-style="western"><surname>Periclou</surname><given-names>AP</given-names></name><name name-style="western"><surname>Sather</surname><given-names>H</given-names></name><name name-style="western"><surname>Bostrom</surname><given-names>BC</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>LJ</given-names></name><etal/></person-group>. <article-title>A randomized comparison of native <italic toggle="yes">Escherichia coli</italic> asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a children's cancer group study</article-title>. <source>Blood</source>. (<year>2002</year>) <volume>99</volume>:<fpage>1986</fpage>&#8211;<lpage>94</lpage>. <pub-id pub-id-type="doi">10.1182/blood.V99.6.1986</pub-id><pub-id pub-id-type="pmid">11877270</pub-id></mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wetzler</surname><given-names>M</given-names></name><name name-style="western"><surname>Sanford</surname><given-names>BL</given-names></name><name name-style="western"><surname>Kurtzberg</surname><given-names>J</given-names></name><name name-style="western"><surname>DeOliveira</surname><given-names>D</given-names></name><name name-style="western"><surname>Frankel</surname><given-names>SR</given-names></name><name name-style="western"><surname>Powell</surname><given-names>BL</given-names></name><etal/></person-group>. <article-title>Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: cancer and leukemia group B study 9511</article-title>. <source>Blood</source>. (<year>2007</year>) <volume>109</volume>:<fpage>4164</fpage>&#8211;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2006-09-045351</pub-id><pub-id pub-id-type="pmid">17264295</pub-id><pub-id pub-id-type="pmcid">PMC1885493</pub-id></mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ehrenforth</surname><given-names>S</given-names></name><name name-style="western"><surname>Kreuz</surname><given-names>W</given-names></name><name name-style="western"><surname>Scharrer</surname><given-names>I</given-names></name><name name-style="western"><surname>Linde</surname><given-names>R</given-names></name><name name-style="western"><surname>Funk</surname><given-names>M</given-names></name><name name-style="western"><surname>Gungor</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs</article-title>. <source>Lancet</source>. (<year>1992</year>) <volume>339</volume>:<fpage>594</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/0140-6736(92)90874-3</pub-id><pub-id pub-id-type="pmid">1347102</pub-id></mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lillicrap</surname><given-names>D</given-names></name><name name-style="western"><surname>Fijnvandraat</surname><given-names>K</given-names></name><name name-style="western"><surname>Santagostino</surname><given-names>E</given-names></name></person-group>. <article-title>Inhibitors - genetic and environmental factors</article-title>. <source>Haemophilia</source>. (<year>2014</year>) <volume>20</volume>(<issue>Suppl. 4</issue>):<fpage>87</fpage>&#8211;<lpage>93</lpage>. <pub-id pub-id-type="doi">10.1111/hae.12412</pub-id><pub-id pub-id-type="pmid">24762282</pub-id></mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haji Abdolvahab</surname><given-names>M</given-names></name><name name-style="western"><surname>Mofrad</surname><given-names>MR</given-names></name><name name-style="western"><surname>Schellekens</surname><given-names>H</given-names></name></person-group>. <article-title>Interferon beta: from molecular level to therapeutic effects</article-title>. <source>Int Rev Cell Mol Biol</source>. (<year>2016</year>) <volume>326</volume>:<fpage>343</fpage>&#8211;<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1016/bs.ircmb.2016.06.001</pub-id><pub-id pub-id-type="pmid">27572132</pub-id></mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nazarov</surname><given-names>VD</given-names></name><name name-style="western"><surname>Lapin</surname><given-names>SV</given-names></name><name name-style="western"><surname>Mazing</surname><given-names>AV</given-names></name><name name-style="western"><surname>Evdoshenko</surname><given-names>EP</given-names></name><name name-style="western"><surname>Totolian</surname><given-names>AA</given-names></name></person-group>. <article-title>Immunogenicity of human interferon-beta-containing pharmaceuticals</article-title>. <source>Biochemistry (Mosc)</source>. (<year>2016</year>) <volume>81</volume>:<fpage>1396</fpage>&#8211;<lpage>400</lpage>. <pub-id pub-id-type="doi">10.1134/S000629791611016X</pub-id><pub-id pub-id-type="pmid">27914464</pub-id></mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Govindappa</surname><given-names>K</given-names></name><name name-style="western"><surname>Sathish</surname><given-names>J</given-names></name><name name-style="western"><surname>Park</surname><given-names>K</given-names></name><name name-style="western"><surname>Kirkham</surname><given-names>J</given-names></name><name name-style="western"><surname>Pirmohamed</surname><given-names>M</given-names></name></person-group>. <article-title>Development of interferon beta-neutralising antibodies in multiple sclerosis&#8211;a systematic review and meta-analysis</article-title>. <source>Eur J Clin Pharmacol</source>. (<year>2015</year>) <volume>71</volume>:<fpage>1287</fpage>&#8211;<lpage>98</lpage>. <pub-id pub-id-type="doi">10.1007/s00228-015-1921-0</pub-id><pub-id pub-id-type="pmid">26268445</pub-id></mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lagasse</surname><given-names>HA</given-names></name><name name-style="western"><surname>Alexaki</surname><given-names>A</given-names></name><name name-style="western"><surname>Simhadri</surname><given-names>VL</given-names></name><name name-style="western"><surname>Katagiri</surname><given-names>NH</given-names></name><name name-style="western"><surname>Jankowski</surname><given-names>W</given-names></name><name name-style="western"><surname>Sauna</surname><given-names>ZE</given-names></name><etal/></person-group>. <article-title>Recent advances in (therapeutic protein) drug development</article-title>. <source>F1000Res</source>. (<year>2017</year>) <volume>6</volume>:<fpage>113</fpage>. <pub-id pub-id-type="doi">10.12688/f1000research.9970.1</pub-id><pub-id pub-id-type="pmid">28232867</pub-id><pub-id pub-id-type="pmcid">PMC5302153</pub-id></mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Buettner</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Shah</surname><given-names>SR</given-names></name><name name-style="western"><surname>Saeui</surname><given-names>CT</given-names></name><name name-style="western"><surname>Ariss</surname><given-names>R</given-names></name><name name-style="western"><surname>Yarema</surname><given-names>KJ</given-names></name></person-group>. <article-title>Improving immunotherapy through glycodesign</article-title>. <source>Front Immunol</source>. (<year>2018</year>) <volume>9</volume>:<fpage>2485</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2018.02485</pub-id><pub-id pub-id-type="pmid">30450094</pub-id><pub-id pub-id-type="pmcid">PMC6224361</pub-id></mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuriakose</surname><given-names>A</given-names></name><name name-style="western"><surname>Chirmule</surname><given-names>N</given-names></name><name name-style="western"><surname>Nair</surname><given-names>P</given-names></name></person-group>. <article-title>Immunogenicity of biotherapeutics: causes and association with posttranslational modifications</article-title>. <source>J Immunol Res</source>. (<year>2016</year>) <volume>2016</volume>:<fpage>1298473</fpage>. <pub-id pub-id-type="doi">10.1155/2016/1298473</pub-id><pub-id pub-id-type="pmid">27437405</pub-id><pub-id pub-id-type="pmcid">PMC4942633</pub-id></mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hilger</surname><given-names>C</given-names></name><name name-style="western"><surname>Fischer</surname><given-names>J</given-names></name><name name-style="western"><surname>Wolbing</surname><given-names>F</given-names></name><name name-style="western"><surname>Biedermann</surname><given-names>T</given-names></name></person-group>. <article-title>Role and mechanism of galactose-alpha-1,3-galactose in the elicitation of delayed anaphylactic reactions to red meat</article-title>. <source>Curr Allergy Asthma Rep</source>. (<year>2019</year>) <volume>19</volume>:<fpage>3</fpage>. <pub-id pub-id-type="doi">10.1007/s11882-019-0835-9</pub-id><pub-id pub-id-type="pmid">30673913</pub-id><pub-id pub-id-type="pmcid">PMC6344609</pub-id></mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peterson</surname><given-names>RG</given-names></name><name name-style="western"><surname>Handschumacher</surname><given-names>RE</given-names></name><name name-style="western"><surname>Mitchell</surname><given-names>MS</given-names></name></person-group>. <article-title>Immunological responses to L-asparaginase</article-title>. <source>J Clin Invest</source>. (<year>1971</year>) <volume>50</volume>:<fpage>1080</fpage>&#8211;<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1172/JCI106579</pub-id><pub-id pub-id-type="pmid">4101590</pub-id><pub-id pub-id-type="pmcid">PMC292030</pub-id></mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Woo</surname><given-names>MH</given-names></name><name name-style="western"><surname>Hak</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Storm</surname><given-names>MC</given-names></name><name name-style="western"><surname>Evans</surname><given-names>WE</given-names></name><name name-style="western"><surname>Sandlund</surname><given-names>JT</given-names></name><name name-style="western"><surname>Rivera</surname><given-names>GK</given-names></name><etal/></person-group>. <article-title>Anti-asparaginase antibodies following E. <italic toggle="yes">coli</italic> asparaginase therapy in pediatric acute lymphoblastic leukemia</article-title>. <source>Leukemia</source>. (<year>1998</year>) <volume>12</volume>:<fpage>1527</fpage>&#8211;<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1038/sj.leu.2401162</pub-id><pub-id pub-id-type="pmid">9766495</pub-id></mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lorentz</surname><given-names>KM</given-names></name><name name-style="western"><surname>Kontos</surname><given-names>S</given-names></name><name name-style="western"><surname>Diaceri</surname><given-names>G</given-names></name><name name-style="western"><surname>Henry</surname><given-names>H</given-names></name><name name-style="western"><surname>Hubbell</surname><given-names>JA</given-names></name></person-group>. <article-title>Engineered binding to erythrocytes induces immunological tolerance to <italic toggle="yes">E. coli asparaginase</italic></article-title>. <source>Sci Adv</source>. (<year>2015</year>) <volume>1</volume>:<fpage>e1500112</fpage>. <pub-id pub-id-type="doi">10.1126/sciadv.1500112</pub-id><pub-id pub-id-type="pmid">26601215</pub-id><pub-id pub-id-type="pmcid">PMC4646778</pub-id></mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pandey</surname><given-names>GS</given-names></name><name name-style="western"><surname>Sauna</surname><given-names>ZE</given-names></name></person-group>. <article-title>Pharmacogenetics and the immunogenicity of protein therapeutics</article-title>. <source>J Interferon Cytokine Res</source>. (<year>2014</year>) <volume>34</volume>:<fpage>931</fpage>&#8211;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1089/jir.2012.0136</pub-id><pub-id pub-id-type="pmid">25493960</pub-id></mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mahlangu</surname><given-names>JN</given-names></name><name name-style="western"><surname>Weldingh</surname><given-names>KN</given-names></name><name name-style="western"><surname>Lentz</surname><given-names>SR</given-names></name><name name-style="western"><surname>Kaicker</surname><given-names>S</given-names></name><name name-style="western"><surname>Karim</surname><given-names>FA</given-names></name><name name-style="western"><surname>Matsushita</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Changes in the amino acid sequence of the recombinant human factor VIIa analog, vatreptacog alfa, are associated with clinical immunogenicity</article-title>. <source>J Thromb Haemost</source>. (<year>2015</year>) <volume>13</volume>:<fpage>1989</fpage>&#8211;<lpage>98</lpage>. <pub-id pub-id-type="doi">10.1111/jth.13141</pub-id><pub-id pub-id-type="pmid">26362483</pub-id></mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bar-Yoseph</surname><given-names>H</given-names></name><name name-style="western"><surname>Pressman</surname><given-names>S</given-names></name><name name-style="western"><surname>Blatt</surname><given-names>A</given-names></name><name name-style="western"><surname>Gerassy Vainberg</surname><given-names>S</given-names></name><name name-style="western"><surname>Maimon</surname><given-names>N</given-names></name><name name-style="western"><surname>Starosvetsky</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Infliximab-tumor necrosis factor complexes elicit formation of anti-drug antibodies</article-title>. <source>Gastroenterology</source>. (<year>2019</year>) <volume>157</volume>:<fpage>1338</fpage>&#8211;<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1053/j.gastro.2019.08.009</pub-id><pub-id pub-id-type="pmid">31401142</pub-id></mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rossert</surname><given-names>J</given-names></name><name name-style="western"><surname>Casadevall</surname><given-names>N</given-names></name><name name-style="western"><surname>Eckardt</surname><given-names>KU</given-names></name></person-group>. <article-title>Anti-erythropoietin antibodies and pure red cell aplasia</article-title>. <source>J Am Soc Nephrol</source>. (<year>2004</year>) <volume>15</volume>:<fpage>398</fpage>&#8211;<lpage>406</lpage>. <pub-id pub-id-type="doi">10.1097/01.ASN.0000107561.59698.42</pub-id><pub-id pub-id-type="pmid">14747386</pub-id></mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schellekens</surname><given-names>H</given-names></name></person-group>. <article-title>Immunologic mechanisms of EPO-associated pure red cell aplasia</article-title>. <source>Best Pract Res Clin Haematol</source>. (<year>2005</year>) <volume>18</volume>:<fpage>473</fpage>&#8211;<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1016/j.beha.2005.01.016</pub-id><pub-id pub-id-type="pmid">15792922</pub-id></mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alexaki</surname><given-names>A</given-names></name><name name-style="western"><surname>Hettiarachchi</surname><given-names>GK</given-names></name><name name-style="western"><surname>Athey</surname><given-names>JC</given-names></name><name name-style="western"><surname>Katneni</surname><given-names>UK</given-names></name><name name-style="western"><surname>Simhadri</surname><given-names>V</given-names></name><name name-style="western"><surname>Hamasaki-Katagiri</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>Effects of codon optimization on coagulation factor IX translation and structure: implications for protein and gene therapies</article-title>. <source>Sci Rep</source>. (<year>2019</year>) <volume>9</volume>:<fpage>15449</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-019-51984-2</pub-id><pub-id pub-id-type="pmid">31664102</pub-id><pub-id pub-id-type="pmcid">PMC6820528</pub-id></mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sethu</surname><given-names>S</given-names></name><name name-style="western"><surname>Govindappa</surname><given-names>K</given-names></name><name name-style="western"><surname>Quinn</surname><given-names>P</given-names></name><name name-style="western"><surname>Wadhwa</surname><given-names>M</given-names></name><name name-style="western"><surname>Stebbings</surname><given-names>R</given-names></name><name name-style="western"><surname>Boggild</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Immunoglobulin G1 and immunoglobulin G4 antibodies in multiple sclerosis patients treated with IFNbeta interact with the endogenous cytokine and activate complement</article-title>. <source>Clin Immunol</source>. (<year>2013</year>) <volume>148</volume>:<fpage>177</fpage>&#8211;<lpage>85</lpage>. <pub-id pub-id-type="doi">10.1016/j.clim.2013.05.008</pub-id><pub-id pub-id-type="pmid">23770627</pub-id><pub-id pub-id-type="pmcid">PMC3779799</pub-id></mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krishna</surname><given-names>M</given-names></name><name name-style="western"><surname>Nadler</surname><given-names>SG</given-names></name></person-group>. <article-title>Immunogenicity to biotherapeutics - the role of anti-drug immune complexes</article-title>. <source>Front Immunol</source>. (<year>2016</year>) <volume>7</volume>:<fpage>21</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2016.00021</pub-id><pub-id pub-id-type="pmid">26870037</pub-id><pub-id pub-id-type="pmcid">PMC4735944</pub-id></mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rojko</surname><given-names>JL</given-names></name><name name-style="western"><surname>Evans</surname><given-names>MG</given-names></name><name name-style="western"><surname>Price</surname><given-names>SA</given-names></name><name name-style="western"><surname>Han</surname><given-names>B</given-names></name><name name-style="western"><surname>Waine</surname><given-names>G</given-names></name><name name-style="western"><surname>DeWitte</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Formation, clearance, deposition, pathogenicity, and identification of biopharmaceutical-related immune complexes: review and case studies</article-title>. <source>Toxicol Pathol</source>. (<year>2014</year>) <volume>42</volume>:<fpage>725</fpage>&#8211;<lpage>64</lpage>. <pub-id pub-id-type="doi">10.1177/0192623314526475</pub-id><pub-id pub-id-type="pmid">24705884</pub-id></mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ducourau</surname><given-names>E</given-names></name><name name-style="western"><surname>Mulleman</surname><given-names>D</given-names></name><name name-style="western"><surname>Paintaud</surname><given-names>G</given-names></name><name name-style="western"><surname>Miow Lin</surname><given-names>DC</given-names></name><name name-style="western"><surname>Lauferon</surname><given-names>F</given-names></name><name name-style="western"><surname>Ternant</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases</article-title>. <source>Arthritis Res Ther</source>. (<year>2011</year>) <volume>13</volume>:<fpage>R105</fpage>. <pub-id pub-id-type="doi">10.1186/ar3386</pub-id><pub-id pub-id-type="pmid">21708018</pub-id><pub-id pub-id-type="pmcid">PMC3218920</pub-id></mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Schouwenburg</surname><given-names>PA</given-names></name><name name-style="western"><surname>van de Stadt</surname><given-names>LA</given-names></name><name name-style="western"><surname>de Jong</surname><given-names>RN</given-names></name><name name-style="western"><surname>van Buren</surname><given-names>EE</given-names></name><name name-style="western"><surname>Kruithof</surname><given-names>S</given-names></name><name name-style="western"><surname>de Groot</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation</article-title>. <source>Ann Rheum Dis</source>. (<year>2013</year>) <volume>72</volume>:<fpage>104</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1136/annrheumdis-2012-201445</pub-id><pub-id pub-id-type="pmid">22759910</pub-id></mixed-citation></ref><ref id="B51"><label>51.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chitlur</surname><given-names>M</given-names></name><name name-style="western"><surname>Warrier</surname><given-names>I</given-names></name><name name-style="western"><surname>Rajpurkar</surname><given-names>M</given-names></name><name name-style="western"><surname>Lusher</surname><given-names>JM</given-names></name></person-group>. <article-title>Inhibitors in factor IX deficiency a report of the ISTH-SSC international FIX inhibitor registry (1997-2006)</article-title>. <source>Haemophilia</source>. (<year>2009</year>) <volume>15</volume>:<fpage>1027</fpage>&#8211;<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2516.2009.02039.x</pub-id><pub-id pub-id-type="pmid">19515028</pub-id></mixed-citation></ref><ref id="B52"><label>52.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McDonald</surname><given-names>JR</given-names></name><name name-style="western"><surname>Renehan</surname><given-names>AG</given-names></name><name name-style="western"><surname>O'Dwyer</surname><given-names>ST</given-names></name><name name-style="western"><surname>Haboubi</surname><given-names>NY</given-names></name></person-group>. <article-title>Lymph node harvest in colon and rectal cancer: current considerations</article-title>. <source>World J Gastrointest Surg</source>. (<year>2012</year>) <volume>4</volume>:<fpage>9</fpage>&#8211;<lpage>19</lpage>. <pub-id pub-id-type="doi">10.4240/wjgs.v4.i1.9</pub-id><pub-id pub-id-type="pmid">22347537</pub-id><pub-id pub-id-type="pmcid">PMC3277879</pub-id></mixed-citation></ref><ref id="B53"><label>53.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thompson</surname><given-names>RH</given-names></name><name name-style="western"><surname>Carver</surname><given-names>BS</given-names></name><name name-style="western"><surname>Bosl</surname><given-names>GJ</given-names></name><name name-style="western"><surname>Bajorin</surname><given-names>D</given-names></name><name name-style="western"><surname>Motzer</surname><given-names>R</given-names></name><name name-style="western"><surname>Feldman</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Body mass index is associated with higher lymph node counts during retroperitoneal lymph node dissection</article-title>. <source>Urology</source>. (<year>2012</year>) <volume>79</volume>:<fpage>361</fpage>&#8211;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1016/j.urology.2011.04.050</pub-id><pub-id pub-id-type="pmid">22173172</pub-id><pub-id pub-id-type="pmcid">PMC4170790</pub-id></mixed-citation></ref><ref id="B54"><label>54.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morikawa</surname><given-names>T</given-names></name><name name-style="western"><surname>Tanaka</surname><given-names>N</given-names></name><name name-style="western"><surname>Kuchiba</surname><given-names>A</given-names></name><name name-style="western"><surname>Nosho</surname><given-names>K</given-names></name><name name-style="western"><surname>Yamauchi</surname><given-names>M</given-names></name><name name-style="western"><surname>Hornick</surname><given-names>JL</given-names></name><etal/></person-group>. <article-title>Predictors of lymph node count in colorectal cancer resections: data from US nationwide prospective cohort studies</article-title>. <source>Arch Surg</source>. (<year>2012</year>) <volume>147</volume>:<fpage>715</fpage>&#8211;<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1001/archsurg.2012.353</pub-id><pub-id pub-id-type="pmid">22508672</pub-id><pub-id pub-id-type="pmcid">PMC3404227</pub-id></mixed-citation></ref><ref id="B55"><label>55.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McFadden</surname><given-names>C</given-names></name><name name-style="western"><surname>McKinley</surname><given-names>B</given-names></name><name name-style="western"><surname>Greenwell</surname><given-names>B</given-names></name><name name-style="western"><surname>Knuckolls</surname><given-names>K</given-names></name><name name-style="western"><surname>Culumovic</surname><given-names>P</given-names></name><name name-style="western"><surname>Schammel</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Differential lymph node retrieval in rectal cancer: associated factors and effect on survival</article-title>. <source>J Gastrointest Oncol</source>. (<year>2013</year>) <volume>4</volume>:<fpage>158</fpage>&#8211;<lpage>63</lpage>. <pub-id pub-id-type="doi">10.3978/j.issn.2078-6891.2013.023</pub-id><pub-id pub-id-type="pmid">23730511</pub-id><pub-id pub-id-type="pmcid">PMC3635191</pub-id></mixed-citation></ref><ref id="B56"><label>56.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chou</surname><given-names>JF</given-names></name><name name-style="western"><surname>Row</surname><given-names>D</given-names></name><name name-style="western"><surname>Gonen</surname><given-names>M</given-names></name><name name-style="western"><surname>Liu</surname><given-names>YH</given-names></name><name name-style="western"><surname>Schrag</surname><given-names>D</given-names></name><name name-style="western"><surname>Weiser</surname><given-names>MR</given-names></name></person-group>. <article-title>Clinical and pathologic factors that predict lymph node yield from surgical specimens in colorectal cancer: a population-based study</article-title>. <source>Cancer</source>. (<year>2010</year>) <volume>116</volume>:<fpage>2560</fpage>&#8211;<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1002/cncr.25032</pub-id><pub-id pub-id-type="pmid">20499400</pub-id><pub-id pub-id-type="pmcid">PMC4067456</pub-id></mixed-citation></ref><ref id="B57"><label>57.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Willard-Mack</surname><given-names>CL</given-names></name></person-group>. <article-title>Normal structure, function, and histology of lymph nodes</article-title>. <source>Toxicol Pathol</source>. (<year>2006</year>) <volume>34</volume>:<fpage>409</fpage>&#8211;<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1080/01926230600867727</pub-id><pub-id pub-id-type="pmid">17067937</pub-id></mixed-citation></ref><ref id="B58"><label>58.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fossum</surname><given-names>S</given-names></name><name name-style="western"><surname>Ford</surname><given-names>WL</given-names></name></person-group>. <article-title>The organization of cell populations within lymph nodes: their origin, life history and functional relationships</article-title>. <source>Histopathology</source>. (<year>1985</year>) <volume>9</volume>:<fpage>469</fpage>&#8211;<lpage>99</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2559.1985.tb02830.x</pub-id><pub-id pub-id-type="pmid">3891574</pub-id></mixed-citation></ref><ref id="B59"><label>59.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mesin</surname><given-names>L</given-names></name><name name-style="western"><surname>Ersching</surname><given-names>J</given-names></name><name name-style="western"><surname>Victora</surname><given-names>GD</given-names></name></person-group>. <article-title>Germinal center B cell dynamics</article-title>. <source>Immunity</source>. (<year>2016</year>) <volume>45</volume>:<fpage>471</fpage>&#8211;<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1016/j.immuni.2016.09.001</pub-id><pub-id pub-id-type="pmid">27653600</pub-id><pub-id pub-id-type="pmcid">PMC5123673</pub-id></mixed-citation></ref><ref id="B60"><label>60.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Victora</surname><given-names>GD</given-names></name><name name-style="western"><surname>Dominguez-Sola</surname><given-names>D</given-names></name><name name-style="western"><surname>Holmes</surname><given-names>AB</given-names></name><name name-style="western"><surname>Deroubaix</surname><given-names>S</given-names></name><name name-style="western"><surname>Dalla-Favera</surname><given-names>R</given-names></name><name name-style="western"><surname>Nussenzweig</surname><given-names>MC</given-names></name></person-group>. <article-title>Identification of human germinal center light and dark zone cells and their relationship to human B-cell lymphomas</article-title>. <source>Blood</source>. (<year>2012</year>) <volume>120</volume>:<fpage>2240</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2012-03-415380</pub-id><pub-id pub-id-type="pmid">22740445</pub-id><pub-id pub-id-type="pmcid">PMC3447782</pub-id></mixed-citation></ref><ref id="B61"><label>61.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mayer</surname><given-names>CT</given-names></name><name name-style="western"><surname>Gazumyan</surname><given-names>A</given-names></name><name name-style="western"><surname>Kara</surname><given-names>EE</given-names></name><name name-style="western"><surname>Gitlin</surname><given-names>AD</given-names></name><name name-style="western"><surname>Golijanin</surname><given-names>J</given-names></name><name name-style="western"><surname>Viant</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>The microanatomic segregation of selection by apoptosis in the germinal center</article-title>. <source>Science</source>. (<year>2017</year>) <volume>358</volume>:<fpage>eaao2602</fpage>. <pub-id pub-id-type="doi">10.1126/science.aao2602</pub-id><pub-id pub-id-type="pmid">28935768</pub-id><pub-id pub-id-type="pmcid">PMC5957278</pub-id></mixed-citation></ref><ref id="B62"><label>62.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bajenoff</surname><given-names>M</given-names></name><name name-style="western"><surname>Glaichenhaus</surname><given-names>N</given-names></name><name name-style="western"><surname>Germain</surname><given-names>RN</given-names></name></person-group>. <article-title>Fibroblastic reticular cells guide T lymphocyte entry into and migration within the splenic T cell zone</article-title>. <source>J Immunol</source>. (<year>2008</year>) <volume>181</volume>:<fpage>3947</fpage>&#8211;<lpage>54</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.181.6.3947</pub-id><pub-id pub-id-type="pmid">18768849</pub-id><pub-id pub-id-type="pmcid">PMC2596721</pub-id></mixed-citation></ref><ref id="B63"><label>63.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Louie</surname><given-names>DAP</given-names></name><name name-style="western"><surname>Liao</surname><given-names>S</given-names></name></person-group>. <article-title>Lymph node subcapsular sinus macrophages as the frontline of lymphatic immune defense</article-title>. <source>Front Immunol</source>. (<year>2019</year>) <volume>10</volume>:<fpage>347</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2019.00347</pub-id><pub-id pub-id-type="pmid">30891035</pub-id><pub-id pub-id-type="pmcid">PMC6413714</pub-id></mixed-citation></ref><ref id="B64"><label>64.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gaya</surname><given-names>M</given-names></name><name name-style="western"><surname>Castello</surname><given-names>A</given-names></name><name name-style="western"><surname>Montaner</surname><given-names>B</given-names></name><name name-style="western"><surname>Rogers</surname><given-names>N</given-names></name><name name-style="western"><surname>Reise Sousa</surname><given-names>C</given-names></name><name name-style="western"><surname>Bruckbauer</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Host response. inflammation-induced disruption of SCS macrophages impairs B cell responses to secondary infection</article-title>. <source>Science</source>. (<year>2015</year>) <volume>347</volume>:<fpage>667</fpage>&#8211;<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1126/science.aaa1300</pub-id><pub-id pub-id-type="pmid">25657250</pub-id></mixed-citation></ref><ref id="B65"><label>65.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barral</surname><given-names>P</given-names></name><name name-style="western"><surname>Polzella</surname><given-names>P</given-names></name><name name-style="western"><surname>Bruckbauer</surname><given-names>A</given-names></name><name name-style="western"><surname>van Rooijen</surname><given-names>N</given-names></name><name name-style="western"><surname>Besra</surname><given-names>GS</given-names></name><name name-style="western"><surname>Cerundolo</surname><given-names>V</given-names></name><etal/></person-group>. <article-title>CD169(+) macrophages present lipid antigens to mediate early activation of iNKT cells in lymph nodes</article-title>. <source>Nat Immunol</source>. (<year>2010</year>) <volume>11</volume>:<fpage>303</fpage>&#8211;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1038/ni.1853</pub-id><pub-id pub-id-type="pmid">20228797</pub-id><pub-id pub-id-type="pmcid">PMC2923071</pub-id></mixed-citation></ref><ref id="B66"><label>66.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jakubzick</surname><given-names>C</given-names></name><name name-style="western"><surname>Gautier</surname><given-names>EL</given-names></name><name name-style="western"><surname>Gibbings</surname><given-names>SL</given-names></name><name name-style="western"><surname>Sojka</surname><given-names>DK</given-names></name><name name-style="western"><surname>Schlitzer</surname><given-names>A</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>TE</given-names></name><etal/></person-group>. <article-title>Minimal differentiation of classical monocytes as they survey steady-state tissues and transport antigen to lymph nodes</article-title>. <source>Immunity</source>. (<year>2013</year>) <volume>39</volume>:<fpage>599</fpage>&#8211;<lpage>610</lpage>. <pub-id pub-id-type="doi">10.1016/j.immuni.2013.08.007</pub-id><pub-id pub-id-type="pmid">24012416</pub-id><pub-id pub-id-type="pmcid">PMC3820017</pub-id></mixed-citation></ref><ref id="B67"><label>67.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheong</surname><given-names>C</given-names></name><name name-style="western"><surname>Matos</surname><given-names>I</given-names></name><name name-style="western"><surname>Choi</surname><given-names>JH</given-names></name><name name-style="western"><surname>Dandamudi</surname><given-names>DB</given-names></name><name name-style="western"><surname>Shrestha</surname><given-names>E</given-names></name><name name-style="western"><surname>Longhi</surname><given-names>MP</given-names></name><etal/></person-group>. <article-title>Microbial stimulation fully differentiates monocytes to DC-SIGN/CD209(+) dendritic cells for immune T cell areas</article-title>. <source>Cell</source>. (<year>2010</year>) <volume>143</volume>:<fpage>416</fpage>&#8211;<lpage>29</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2010.09.039</pub-id><pub-id pub-id-type="pmid">21029863</pub-id><pub-id pub-id-type="pmcid">PMC3150728</pub-id></mixed-citation></ref><ref id="B68"><label>68.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Q</given-names></name><name name-style="western"><surname>Snapper</surname><given-names>CM</given-names></name></person-group>. <article-title>Inflammatory monocytes are critical for induction of a polysaccharide-specific antibody response to an intact bacterium</article-title>. <source>J Immunol</source>. (<year>2013</year>) <volume>190</volume>:<fpage>1048</fpage>&#8211;<lpage>55</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.1202455</pub-id><pub-id pub-id-type="pmid">23269244</pub-id><pub-id pub-id-type="pmcid">PMC3549225</pub-id></mixed-citation></ref><ref id="B69"><label>69.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baratin</surname><given-names>M</given-names></name><name name-style="western"><surname>Simon</surname><given-names>L</given-names></name><name name-style="western"><surname>Jorquera</surname><given-names>A</given-names></name><name name-style="western"><surname>Ghigo</surname><given-names>C</given-names></name><name name-style="western"><surname>Dembele</surname><given-names>D</given-names></name><name name-style="western"><surname>Nowak</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>T cell zone resident macrophages silently dispose of apoptotic cells in the lymph node</article-title>. <source>Immunity</source>. (<year>2017</year>) <volume>47</volume>:<fpage>349</fpage>&#8211;<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1016/j.immuni.2017.07.019</pub-id><pub-id pub-id-type="pmid">28801233</pub-id></mixed-citation></ref><ref id="B70"><label>70.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mohr</surname><given-names>E</given-names></name><name name-style="western"><surname>Serre</surname><given-names>K</given-names></name><name name-style="western"><surname>Manz</surname><given-names>RA</given-names></name><name name-style="western"><surname>Cunningham</surname><given-names>AF</given-names></name><name name-style="western"><surname>Khan</surname><given-names>M</given-names></name><name name-style="western"><surname>Hardie</surname><given-names>DL</given-names></name><etal/></person-group>. <article-title>Dendritic cells and monocyte/macrophages that create the IL-6/APRIL-rich lymph node microenvironments where plasmablasts mature</article-title>. <source>J Immunol</source>. (<year>2009</year>) <volume>182</volume>:<fpage>2113</fpage>&#8211;<lpage>23</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.0802771</pub-id><pub-id pub-id-type="pmid">19201864</pub-id></mixed-citation></ref><ref id="B71"><label>71.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Choi</surname><given-names>YS</given-names></name><name name-style="western"><surname>Eto</surname><given-names>D</given-names></name><name name-style="western"><surname>Yang</surname><given-names>JA</given-names></name><name name-style="western"><surname>Lao</surname><given-names>C</given-names></name><name name-style="western"><surname>Crotty</surname><given-names>S</given-names></name></person-group>. <article-title>Cutting edge: STAT1 is required for IL-6-mediated Bcl6 induction for early follicular helper cell differentiation</article-title>. <source>J Immunol</source>. (<year>2013</year>) <volume>190</volume>:<fpage>3049</fpage>&#8211;<lpage>53</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.1203032</pub-id><pub-id pub-id-type="pmid">23447690</pub-id><pub-id pub-id-type="pmcid">PMC3626564</pub-id></mixed-citation></ref><ref id="B72"><label>72.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Forster</surname><given-names>R</given-names></name><name name-style="western"><surname>Davalos-Misslitz</surname><given-names>AC</given-names></name><name name-style="western"><surname>Rot</surname><given-names>A</given-names></name></person-group>. <article-title>CCR7 and its ligands: balancing immunity and tolerance</article-title>. <source>Nat Rev Immunol</source>. (<year>2008</year>) <volume>8</volume>:<fpage>362</fpage>&#8211;<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1038/nri2297</pub-id><pub-id pub-id-type="pmid">18379575</pub-id></mixed-citation></ref><ref id="B73"><label>73.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hauser</surname><given-names>MA</given-names></name><name name-style="western"><surname>Legler</surname><given-names>DF</given-names></name></person-group>. <article-title>Common and biased signaling pathways of the chemokine receptor CCR7 elicited by its ligands CCL19 and CCL21 in leukocytes</article-title>. <source>J Leukoc Biol</source>. (<year>2016</year>) <volume>99</volume>:<fpage>869</fpage>&#8211;<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1189/jlb.2MR0815-380R</pub-id><pub-id pub-id-type="pmid">26729814</pub-id></mixed-citation></ref><ref id="B74"><label>74.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Comerford</surname><given-names>I</given-names></name><name name-style="western"><surname>Harata-Lee</surname><given-names>Y</given-names></name><name name-style="western"><surname>Bunting</surname><given-names>MD</given-names></name><name name-style="western"><surname>Gregor</surname><given-names>C</given-names></name><name name-style="western"><surname>Kara</surname><given-names>EE</given-names></name><name name-style="western"><surname>McColl</surname><given-names>SR</given-names></name></person-group>. <article-title>A myriad of functions and complex regulation of the CCR7/CCL19/CCL21 chemokine axis in the adaptive immune system</article-title>. <source>Cytokine Growth Factor Rev</source>. (<year>2013</year>) <volume>24</volume>:<fpage>269</fpage>&#8211;<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1016/j.cytogfr.2013.03.001</pub-id><pub-id pub-id-type="pmid">23587803</pub-id></mixed-citation></ref><ref id="B75"><label>75.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Donovan</surname><given-names>GM</given-names></name><name name-style="western"><surname>Lythe</surname><given-names>G</given-names></name></person-group>. <article-title>T cell and reticular network co-dependence in HIV infection</article-title>. <source>J Theor Biol</source>. (<year>2016</year>) <volume>395</volume>:<fpage>211</fpage>&#8211;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1016/j.jtbi.2016.01.040</pub-id><pub-id pub-id-type="pmid">26874227</pub-id></mixed-citation></ref><ref id="B76"><label>76.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Link</surname><given-names>A</given-names></name><name name-style="western"><surname>Vogt</surname><given-names>TK</given-names></name><name name-style="western"><surname>Favre</surname><given-names>S</given-names></name><name name-style="western"><surname>Britschgi</surname><given-names>MR</given-names></name><name name-style="western"><surname>Acha-Orbea</surname><given-names>H</given-names></name><name name-style="western"><surname>Hinz</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Fibroblastic reticular cells in lymph nodes regulate the homeostasis of naive T cells</article-title>. <source>Nat Immunol</source>. (<year>2007</year>) <volume>8</volume>:<fpage>1255</fpage>&#8211;<lpage>65</lpage>. <pub-id pub-id-type="doi">10.1038/ni1513</pub-id><pub-id pub-id-type="pmid">17893676</pub-id></mixed-citation></ref><ref id="B77"><label>77.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gerner</surname><given-names>MY</given-names></name><name name-style="western"><surname>Casey</surname><given-names>KA</given-names></name><name name-style="western"><surname>Kastenmuller</surname><given-names>W</given-names></name><name name-style="western"><surname>Germain</surname><given-names>RN</given-names></name></person-group>. <article-title>Dendritic cell and antigen dispersal landscapes regulate T cell immunity</article-title>. <source>J Exp Med</source>. (<year>2017</year>) <volume>214</volume>:<fpage>3105</fpage>&#8211;<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1084/jem.20170335</pub-id><pub-id pub-id-type="pmid">28847868</pub-id><pub-id pub-id-type="pmcid">PMC5626399</pub-id></mixed-citation></ref><ref id="B78"><label>78.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Groom</surname><given-names>JR</given-names></name><name name-style="western"><surname>Richmond</surname><given-names>J</given-names></name><name name-style="western"><surname>Murooka</surname><given-names>TT</given-names></name><name name-style="western"><surname>Sorensen</surname><given-names>EW</given-names></name><name name-style="western"><surname>Sung</surname><given-names>JH</given-names></name><name name-style="western"><surname>Bankert</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>CXCR3 chemokine receptor-ligand interactions in the lymph node optimize CD4+ T helper 1 cell differentiation</article-title>. <source>Immunity</source>. (<year>2012</year>) <volume>37</volume>:<fpage>1091</fpage>&#8211;<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1016/j.immuni.2012.08.016</pub-id><pub-id pub-id-type="pmid">23123063</pub-id><pub-id pub-id-type="pmcid">PMC3525757</pub-id></mixed-citation></ref><ref id="B79"><label>79.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Okada</surname><given-names>T</given-names></name><name name-style="western"><surname>Miller</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Parker</surname><given-names>I</given-names></name><name name-style="western"><surname>Krummel</surname><given-names>MF</given-names></name><name name-style="western"><surname>Neighbors</surname><given-names>M</given-names></name><name name-style="western"><surname>Hartley</surname><given-names>SB</given-names></name><etal/></person-group>. <article-title>Antigen-engaged B cells undergo chemotaxis toward the T zone and form motile conjugates with helper T cells</article-title>. <source>PLoS Biol</source>. (<year>2005</year>) <volume>3</volume>:<fpage>e150</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pbio.0030150</pub-id><pub-id pub-id-type="pmid">15857154</pub-id><pub-id pub-id-type="pmcid">PMC1088276</pub-id></mixed-citation></ref><ref id="B80"><label>80.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haynes</surname><given-names>NM</given-names></name><name name-style="western"><surname>Allen</surname><given-names>CD</given-names></name><name name-style="western"><surname>Lesley</surname><given-names>R</given-names></name><name name-style="western"><surname>Ansel</surname><given-names>KM</given-names></name><name name-style="western"><surname>Killeen</surname><given-names>N</given-names></name><name name-style="western"><surname>Cyster</surname><given-names>JG</given-names></name></person-group>. <article-title>Role of CXCR5 and CCR7 in follicular Th cell positioning and appearance of a programmed cell death gene-1high germinal center-associated subpopulation</article-title>. <source>J Immunol</source>. (<year>2007</year>) <volume>179</volume>:<fpage>5099</fpage>&#8211;<lpage>108</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.179.8.5099</pub-id><pub-id pub-id-type="pmid">17911595</pub-id></mixed-citation></ref><ref id="B81"><label>81.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ballesteros-Tato</surname><given-names>A</given-names></name><name name-style="western"><surname>Leon</surname><given-names>B</given-names></name><name name-style="western"><surname>Lund</surname><given-names>FE</given-names></name><name name-style="western"><surname>Randall</surname><given-names>TD</given-names></name></person-group>. <article-title>CD4+ T helper cells use CD154-CD40 interactions to counteract T reg cell-mediated suppression of CD8+ T cell responses to influenza</article-title>. <source>J Exp Med</source>. (<year>2013</year>) <volume>210</volume>:<fpage>1591</fpage>&#8211;<lpage>601</lpage>. <pub-id pub-id-type="doi">10.1084/jem.20130097</pub-id><pub-id pub-id-type="pmid">23835849</pub-id><pub-id pub-id-type="pmcid">PMC3727323</pub-id></mixed-citation></ref><ref id="B82"><label>82.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eivazi</surname><given-names>S</given-names></name><name name-style="western"><surname>Bagheri</surname><given-names>S</given-names></name><name name-style="western"><surname>Hashemzadeh</surname><given-names>MS</given-names></name><name name-style="western"><surname>Ghalavand</surname><given-names>M</given-names></name><name name-style="western"><surname>Qamsari</surname><given-names>ES</given-names></name><name name-style="western"><surname>Dorostkar</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Development of T follicular helper cells and their role in disease and immune system</article-title>. <source>Biomed Pharmacother</source>. (<year>2016</year>) <volume>84</volume>:<fpage>1668</fpage>&#8211;<lpage>78</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopha.2016.10.083</pub-id><pub-id pub-id-type="pmid">27863842</pub-id></mixed-citation></ref><ref id="B83"><label>83.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shih</surname><given-names>TA</given-names></name><name name-style="western"><surname>Meffre</surname><given-names>E</given-names></name><name name-style="western"><surname>Roederer</surname><given-names>M</given-names></name><name name-style="western"><surname>Nussenzweig</surname><given-names>MC</given-names></name></person-group>. <article-title>Role of BCR affinity in T cell dependent antibody responses in vivo</article-title>. <source>Nat Immunol</source>. (<year>2002</year>) <volume>3</volume>:<fpage>570</fpage>&#8211;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1038/ni803</pub-id><pub-id pub-id-type="pmid">12021782</pub-id></mixed-citation></ref><ref id="B84"><label>84.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schwickert</surname><given-names>TA</given-names></name><name name-style="western"><surname>Victora</surname><given-names>GD</given-names></name><name name-style="western"><surname>Fooksman</surname><given-names>DR</given-names></name><name name-style="western"><surname>Kamphorst</surname><given-names>AO</given-names></name><name name-style="western"><surname>Mugnier</surname><given-names>MR</given-names></name><name name-style="western"><surname>Gitlin</surname><given-names>AD</given-names></name><etal/></person-group>. <article-title>A dynamic T cell-limited checkpoint regulates affinity-dependent B cell entry into the germinal center</article-title>. <source>J Exp Med</source>. (<year>2011</year>) <volume>208</volume>:<fpage>1243</fpage>&#8211;<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1084/jem.20102477</pub-id><pub-id pub-id-type="pmid">21576382</pub-id><pub-id pub-id-type="pmcid">PMC3173244</pub-id></mixed-citation></ref><ref id="B85"><label>85.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hale</surname><given-names>JS</given-names></name><name name-style="western"><surname>Youngblood</surname><given-names>B</given-names></name><name name-style="western"><surname>Latner</surname><given-names>DR</given-names></name><name name-style="western"><surname>Mohammed</surname><given-names>AU</given-names></name><name name-style="western"><surname>Ye</surname><given-names>L</given-names></name><name name-style="western"><surname>Akondy</surname><given-names>RS</given-names></name><etal/></person-group>. <article-title>Distinct memory CD4+ T cells with commitment to T follicular helper- and T helper 1-cell lineages are generated after acute viral infection</article-title>. <source>Immunity</source>. (<year>2013</year>) <volume>38</volume>:<fpage>805</fpage>&#8211;<lpage>17</lpage>. <pub-id pub-id-type="doi">10.1016/j.immuni.2013.02.020</pub-id><pub-id pub-id-type="pmid">23583644</pub-id><pub-id pub-id-type="pmcid">PMC3741679</pub-id></mixed-citation></ref><ref id="B86"><label>86.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garside</surname><given-names>P</given-names></name><name name-style="western"><surname>Ingulli</surname><given-names>E</given-names></name><name name-style="western"><surname>Merica</surname><given-names>RR</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>JG</given-names></name><name name-style="western"><surname>Noelle</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Jenkins</surname><given-names>MK</given-names></name></person-group>. <article-title>Visualization of specific B and T lymphocyte interactions in the lymph node</article-title>. <source>Science</source>. (<year>1998</year>) <volume>281</volume>:<fpage>96</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1126/science.281.5373.96</pub-id><pub-id pub-id-type="pmid">9651253</pub-id></mixed-citation></ref><ref id="B87"><label>87.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Suan</surname><given-names>D</given-names></name><name name-style="western"><surname>Sundling</surname><given-names>C</given-names></name><name name-style="western"><surname>Brink</surname><given-names>R</given-names></name></person-group>. <article-title>Plasma cell and memory B cell differentiation from the germinal center</article-title>. <source>Curr Opin Immunol</source>. (<year>2017</year>) <volume>45</volume>:<fpage>97</fpage>&#8211;<lpage>102</lpage>. <pub-id pub-id-type="doi">10.1016/j.coi.2017.03.006</pub-id><pub-id pub-id-type="pmid">28319733</pub-id></mixed-citation></ref><ref id="B88"><label>88.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Silva</surname><given-names>NS</given-names></name><name name-style="western"><surname>Klein</surname><given-names>U</given-names></name></person-group>. <article-title>Dynamics of B cells in germinal centres</article-title>. <source>Nat Rev Immunol</source>. (<year>2015</year>) <volume>15</volume>:<fpage>137</fpage>&#8211;<lpage>48</lpage>. <pub-id pub-id-type="doi">10.1038/nri3804</pub-id><pub-id pub-id-type="pmid">25656706</pub-id><pub-id pub-id-type="pmcid">PMC4399774</pub-id></mixed-citation></ref><ref id="B89"><label>89.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Garcia-Ibanez</surname><given-names>L</given-names></name><name name-style="western"><surname>Toellner</surname><given-names>KM</given-names></name></person-group>. <article-title>Regulation of germinal center B-cell differentiation</article-title>. <source>Immunol Rev</source>. (<year>2016</year>) <volume>270</volume>:<fpage>8</fpage>&#8211;<lpage>19</lpage>. <pub-id pub-id-type="doi">10.1111/imr.12396</pub-id><pub-id pub-id-type="pmid">26864101</pub-id><pub-id pub-id-type="pmcid">PMC4755139</pub-id></mixed-citation></ref><ref id="B90"><label>90.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Muppidi</surname><given-names>JR</given-names></name><name name-style="western"><surname>Lu</surname><given-names>E</given-names></name><name name-style="western"><surname>Cyster</surname><given-names>JG</given-names></name></person-group>. <article-title>The G protein-coupled receptor P2RY8 and follicular dendritic cells promote germinal center confinement of B cells, whereas S1PR3 can contribute to their dissemination</article-title>. <source>J Exp Med</source>. (<year>2015</year>) <volume>212</volume>:<fpage>2213</fpage>&#8211;<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1084/jem.20151250</pub-id><pub-id pub-id-type="pmid">26573295</pub-id><pub-id pub-id-type="pmcid">PMC4689170</pub-id></mixed-citation></ref><ref id="B91"><label>91.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>E</given-names></name><name name-style="western"><surname>Cyster</surname><given-names>JG</given-names></name></person-group>. <article-title>G-protein coupled receptors and ligands that organize humoral immune responses</article-title>. <source>Immunol Rev</source>. (<year>2019</year>) <volume>289</volume>:<fpage>158</fpage>&#8211;<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1111/imr.12743</pub-id><pub-id pub-id-type="pmid">30977196</pub-id><pub-id pub-id-type="pmcid">PMC6464390</pub-id></mixed-citation></ref><ref id="B92"><label>92.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Cho</surname><given-names>B</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>K</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Green</surname><given-names>JA</given-names></name><name name-style="western"><surname>An</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Follicular dendritic cells help establish follicle identity and promote B cell retention in germinal centers</article-title>. <source>J Exp Med</source>. (<year>2011</year>) <volume>208</volume>:<fpage>2497</fpage>&#8211;<lpage>510</lpage>. <pub-id pub-id-type="doi">10.1084/jem.20111449</pub-id><pub-id pub-id-type="pmid">22042977</pub-id><pub-id pub-id-type="pmcid">PMC3256970</pub-id></mixed-citation></ref><ref id="B93"><label>93.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lindhout</surname><given-names>E</given-names></name><name name-style="western"><surname>Mevissen</surname><given-names>ML</given-names></name><name name-style="western"><surname>Kwekkeboom</surname><given-names>J</given-names></name><name name-style="western"><surname>Tager</surname><given-names>JM</given-names></name><name name-style="western"><surname>de Groot</surname><given-names>C</given-names></name></person-group>. <article-title>Direct evidence that human follicular dendritic cells (FDC) rescue germinal centre B cells from death by apoptosis</article-title>. <source>Clin Exp Immunol</source>. (<year>1993</year>) <volume>91</volume>:<fpage>330</fpage>&#8211;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2249.1993.tb05904.x</pub-id><pub-id pub-id-type="pmid">8428399</pub-id><pub-id pub-id-type="pmcid">PMC1554674</pub-id></mixed-citation></ref><ref id="B94"><label>94.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lindhout</surname><given-names>E</given-names></name><name name-style="western"><surname>de Groot</surname><given-names>C</given-names></name></person-group>. <article-title>Follicular dendritic cells and apoptosis: life and death in the germinal centre</article-title>. <source>Histochem J</source>. (<year>1995</year>) <volume>27</volume>:<fpage>167</fpage>&#8211;<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1007/BF00177584</pub-id><pub-id pub-id-type="pmid">7797422</pub-id></mixed-citation></ref><ref id="B95"><label>95.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>YJ</given-names></name><name name-style="western"><surname>Mason</surname><given-names>DY</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>GD</given-names></name><name name-style="western"><surname>Abbot</surname><given-names>S</given-names></name><name name-style="western"><surname>Gregory</surname><given-names>CD</given-names></name><name name-style="western"><surname>Hardie</surname><given-names>DL</given-names></name><etal/></person-group>. <article-title>Germinal center cells express bcl-2 protein after activation by signals which prevent their entry into apoptosis</article-title>. <source>Eur J Immunol</source>. (<year>1991</year>) <volume>21</volume>:<fpage>1905</fpage>&#8211;<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1002/eji.1830210819</pub-id><pub-id pub-id-type="pmid">1868875</pub-id></mixed-citation></ref><ref id="B96"><label>96.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schwarz</surname><given-names>YX</given-names></name><name name-style="western"><surname>Yang</surname><given-names>M</given-names></name><name name-style="western"><surname>Qin</surname><given-names>D</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J</given-names></name><name name-style="western"><surname>Jarvis</surname><given-names>WD</given-names></name><name name-style="western"><surname>Grant</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Follicular dendritic cells protect malignant B cells from apoptosis induced by anti-Fas and antineoplastic agents</article-title>. <source>J Immunol</source>. (<year>1999</year>) <volume>163</volume>:<fpage>6442</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">10586034</pub-id></mixed-citation></ref><ref id="B97"><label>97.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qin</surname><given-names>D</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J</given-names></name><name name-style="western"><surname>Burton</surname><given-names>GF</given-names></name><name name-style="western"><surname>Szakal</surname><given-names>AK</given-names></name><name name-style="western"><surname>Tew</surname><given-names>JG</given-names></name></person-group>. <article-title>Follicular dendritic cells mediated maintenance of primary lymphocyte cultures for long-term analysis of a functional in vitro immune system</article-title>. <source>J Immunol Methods</source>. (<year>1999</year>) <volume>226</volume>:<fpage>19</fpage>&#8211;<lpage>27</lpage>. <pub-id pub-id-type="doi">10.1016/S0022-1759(99)00038-1</pub-id><pub-id pub-id-type="pmid">10410968</pub-id></mixed-citation></ref><ref id="B98"><label>98.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sabri</surname><given-names>F</given-names></name><name name-style="western"><surname>Prados</surname><given-names>A</given-names></name><name name-style="western"><surname>Munoz-Fernandez</surname><given-names>R</given-names></name><name name-style="western"><surname>Lantto</surname><given-names>R</given-names></name><name name-style="western"><surname>Fernandez-Rubio</surname><given-names>P</given-names></name><name name-style="western"><surname>Nasi</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Impaired B cells survival upon production of inflammatory cytokines by HIV-1 exposed follicular dendritic cells</article-title>. <source>Retrovirology</source>. (<year>2016</year>) <volume>13</volume>:<fpage>61</fpage>. <pub-id pub-id-type="doi">10.1186/s12977-016-0295-4</pub-id><pub-id pub-id-type="pmid">27596745</pub-id><pub-id pub-id-type="pmcid">PMC5011926</pub-id></mixed-citation></ref><ref id="B99"><label>99.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garin</surname><given-names>A</given-names></name><name name-style="western"><surname>Meyer-Hermann</surname><given-names>M</given-names></name><name name-style="western"><surname>Contie</surname><given-names>M</given-names></name><name name-style="western"><surname>Figge</surname><given-names>MT</given-names></name><name name-style="western"><surname>Buatois</surname><given-names>V</given-names></name><name name-style="western"><surname>Gunzer</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Toll-like receptor 4 signaling by follicular dendritic cells is pivotal for germinal center onset and affinity maturation</article-title>. <source>Immunity</source>. (<year>2010</year>) <volume>33</volume>:<fpage>84</fpage>&#8211;<lpage>95</lpage>. <pub-id pub-id-type="doi">10.1016/j.immuni.2010.07.005</pub-id><pub-id pub-id-type="pmid">20643339</pub-id></mixed-citation></ref><ref id="B100"><label>100.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bronnimann</surname><given-names>MP</given-names></name><name name-style="western"><surname>Skinner</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Connick</surname><given-names>E</given-names></name></person-group>. <article-title>The B-cell follicle in HIV infection: barrier to a cure</article-title>. <source>Front Immunol</source>. (<year>2018</year>) <volume>9</volume>:<fpage>20</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2018.00020</pub-id><pub-id pub-id-type="pmid">29422894</pub-id><pub-id pub-id-type="pmcid">PMC5788973</pub-id></mixed-citation></ref><ref id="B101"><label>101.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heesters</surname><given-names>BA</given-names></name><name name-style="western"><surname>Chatterjee</surname><given-names>P</given-names></name><name name-style="western"><surname>Kim</surname><given-names>YA</given-names></name><name name-style="western"><surname>Gonzalez</surname><given-names>SF</given-names></name><name name-style="western"><surname>Kuligowski</surname><given-names>MP</given-names></name><name name-style="western"><surname>Kirchhausen</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Endocytosis and recycling of immune complexes by follicular dendritic cells enhances B cell antigen binding and activation</article-title>. <source>Immunity</source>. (<year>2013</year>) <volume>38</volume>:<fpage>1164</fpage>&#8211;<lpage>75</lpage>. <pub-id pub-id-type="doi">10.1016/j.immuni.2013.02.023</pub-id><pub-id pub-id-type="pmid">23770227</pub-id><pub-id pub-id-type="pmcid">PMC3773956</pub-id></mixed-citation></ref><ref id="B102"><label>102.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heesters</surname><given-names>BA</given-names></name><name name-style="western"><surname>Myers</surname><given-names>RC</given-names></name><name name-style="western"><surname>Carroll</surname><given-names>MC</given-names></name></person-group>. <article-title>Follicular dendritic cells: dynamic antigen libraries</article-title>. <source>Nat Rev Immunol</source>. (<year>2014</year>) <volume>14</volume>:<fpage>495</fpage>&#8211;<lpage>504</lpage>. <pub-id pub-id-type="doi">10.1038/nri3689</pub-id><pub-id pub-id-type="pmid">24948364</pub-id></mixed-citation></ref><ref id="B103"><label>103.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Crotty</surname><given-names>S</given-names></name></person-group>. <article-title>T follicular helper cell differentiation, function, and roles in disease</article-title>. <source>Immunity</source>. (<year>2014</year>) <volume>41</volume>:<fpage>529</fpage>&#8211;<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1016/j.immuni.2014.10.004</pub-id><pub-id pub-id-type="pmid">25367570</pub-id><pub-id pub-id-type="pmcid">PMC4223692</pub-id></mixed-citation></ref><ref id="B104"><label>104.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>CH</given-names></name><name name-style="western"><surname>Lim</surname><given-names>HW</given-names></name><name name-style="western"><surname>Kim</surname><given-names>JR</given-names></name><name name-style="western"><surname>Rott</surname><given-names>L</given-names></name><name name-style="western"><surname>Hillsamer</surname><given-names>P</given-names></name><name name-style="western"><surname>Butcher</surname><given-names>EC</given-names></name></person-group>. <article-title>Unique gene expression program of human germinal center T helper cells</article-title>. <source>Blood</source>. (<year>2004</year>) <volume>104</volume>:<fpage>1952</fpage>&#8211;<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2004-03-1206</pub-id><pub-id pub-id-type="pmid">15213097</pub-id></mixed-citation></ref><ref id="B105"><label>105.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Crotty</surname><given-names>S</given-names></name></person-group>. <article-title>Follicular helper CD4 T cells (TFH)</article-title>. <source>Annu Rev Immunol</source>. (<year>2011</year>) <volume>29</volume>:<fpage>621</fpage>&#8211;<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-immunol-031210-101400</pub-id><pub-id pub-id-type="pmid">21314428</pub-id></mixed-citation></ref><ref id="B106"><label>106.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Breitfeld</surname><given-names>D</given-names></name><name name-style="western"><surname>Ohl</surname><given-names>L</given-names></name><name name-style="western"><surname>Kremmer</surname><given-names>E</given-names></name><name name-style="western"><surname>Ellwart</surname><given-names>J</given-names></name><name name-style="western"><surname>Sallusto</surname><given-names>F</given-names></name><name name-style="western"><surname>Lipp</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Follicular B helper T cells express CXC chemokine receptor 5, localize to B cell follicles, and support immunoglobulin production</article-title>. <source>J Exp Med</source>. (<year>2000</year>) <volume>192</volume>:<fpage>1545</fpage>&#8211;<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1084/jem.192.11.1545</pub-id><pub-id pub-id-type="pmid">11104797</pub-id><pub-id pub-id-type="pmcid">PMC2193094</pub-id></mixed-citation></ref><ref id="B107"><label>107.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>CH</given-names></name><name name-style="western"><surname>Rott</surname><given-names>LS</given-names></name><name name-style="western"><surname>Clark-Lewis</surname><given-names>I</given-names></name><name name-style="western"><surname>Campbell</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Wu</surname><given-names>L</given-names></name><name name-style="western"><surname>Butcher</surname><given-names>EC</given-names></name></person-group>. <article-title>Subspecialization of CXCR5+ T cells: B helper activity is focused in a germinal center-localized subset of CXCR5+ T cells</article-title>. <source>J Exp Med</source>. (<year>2001</year>) <volume>193</volume>:<fpage>1373</fpage>&#8211;<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1084/jem.193.12.1373</pub-id><pub-id pub-id-type="pmid">11413192</pub-id><pub-id pub-id-type="pmcid">PMC2193300</pub-id></mixed-citation></ref><ref id="B108"><label>108.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rasheed</surname><given-names>AU</given-names></name><name name-style="western"><surname>Rahn</surname><given-names>HP</given-names></name><name name-style="western"><surname>Sallusto</surname><given-names>F</given-names></name><name name-style="western"><surname>Lipp</surname><given-names>M</given-names></name><name name-style="western"><surname>Muller</surname><given-names>G</given-names></name></person-group>. <article-title>Follicular B helper T cell activity is confined to CXCR5(hi)ICOS(hi) CD4 T cells and is independent of CD57 expression</article-title>. <source>Eur J Immunol</source>. (<year>2006</year>) <volume>36</volume>:<fpage>1892</fpage>&#8211;<lpage>903</lpage>. <pub-id pub-id-type="doi">10.1002/eji.200636136</pub-id><pub-id pub-id-type="pmid">16791882</pub-id></mixed-citation></ref><ref id="B109"><label>109.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kenefeck</surname><given-names>R</given-names></name><name name-style="western"><surname>Wang</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Kapadi</surname><given-names>T</given-names></name><name name-style="western"><surname>Wardzinski</surname><given-names>L</given-names></name><name name-style="western"><surname>Attridge</surname><given-names>K</given-names></name><name name-style="western"><surname>Clough</surname><given-names>LE</given-names></name><etal/></person-group>. <article-title>Follicular helper T cell signature in type 1 diabetes</article-title>. <source>J Clin Invest</source>. (<year>2015</year>) <volume>125</volume>:<fpage>292</fpage>&#8211;<lpage>303</lpage>. <pub-id pub-id-type="doi">10.1172/JCI76238</pub-id><pub-id pub-id-type="pmid">25485678</pub-id><pub-id pub-id-type="pmcid">PMC4382272</pub-id></mixed-citation></ref><ref id="B110"><label>110.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johnston</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Poholek</surname><given-names>AC</given-names></name><name name-style="western"><surname>DiToro</surname><given-names>D</given-names></name><name name-style="western"><surname>Yusuf</surname><given-names>I</given-names></name><name name-style="western"><surname>Eto</surname><given-names>D</given-names></name><name name-style="western"><surname>Barnett</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Bcl6 and Blimp-1 are reciprocal and antagonistic regulators of T follicular helper cell differentiation</article-title>. <source>Science</source>. (<year>2009</year>) <volume>325</volume>:<fpage>1006</fpage>&#8211;<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1126/science.1175870</pub-id><pub-id pub-id-type="pmid">19608860</pub-id><pub-id pub-id-type="pmcid">PMC2766560</pub-id></mixed-citation></ref><ref id="B111"><label>111.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nurieva</surname><given-names>RI</given-names></name><name name-style="western"><surname>Chung</surname><given-names>Y</given-names></name><name name-style="western"><surname>Martinez</surname><given-names>GJ</given-names></name><name name-style="western"><surname>Yang</surname><given-names>XO</given-names></name><name name-style="western"><surname>Tanaka</surname><given-names>S</given-names></name><name name-style="western"><surname>Matskevitch</surname><given-names>TD</given-names></name><etal/></person-group>. <article-title>Bcl6 mediates the development of T follicular helper cells</article-title>. <source>Science</source>. (<year>2009</year>) <volume>325</volume>:<fpage>1001</fpage>&#8211;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1126/science.1176676</pub-id><pub-id pub-id-type="pmid">19628815</pub-id><pub-id pub-id-type="pmcid">PMC2857334</pub-id></mixed-citation></ref><ref id="B112"><label>112.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>D</given-names></name><name name-style="western"><surname>Rao</surname><given-names>S</given-names></name><name name-style="western"><surname>Tsai</surname><given-names>LM</given-names></name><name name-style="western"><surname>Lee</surname><given-names>SK</given-names></name><name name-style="western"><surname>He</surname><given-names>Y</given-names></name><name name-style="western"><surname>Sutcliffe</surname><given-names>EL</given-names></name><etal/></person-group>. <article-title>The transcriptional repressor Bcl-6 directs T follicular helper cell lineage commitment</article-title>. <source>Immunity</source>. (<year>2009</year>) <volume>31</volume>:<fpage>457</fpage>&#8211;<lpage>68</lpage>. <pub-id pub-id-type="doi">10.1016/j.immuni.2009.07.002</pub-id><pub-id pub-id-type="pmid">19631565</pub-id></mixed-citation></ref><ref id="B113"><label>113.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Linterman</surname><given-names>MA</given-names></name><name name-style="western"><surname>Beaton</surname><given-names>L</given-names></name><name name-style="western"><surname>Yu</surname><given-names>D</given-names></name><name name-style="western"><surname>Ramiscal</surname><given-names>RR</given-names></name><name name-style="western"><surname>Srivastava</surname><given-names>M</given-names></name><name name-style="western"><surname>Hogan</surname><given-names>JJ</given-names></name><etal/></person-group>. <article-title>IL-21 acts directly on B cells to regulate Bcl-6 expression and germinal center responses</article-title>. <source>J Exp Med</source>. (<year>2010</year>) <volume>207</volume>:<fpage>353</fpage>&#8211;<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1084/jem.20091738</pub-id><pub-id pub-id-type="pmid">20142429</pub-id><pub-id pub-id-type="pmcid">PMC2822609</pub-id></mixed-citation></ref><ref id="B114"><label>114.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zotos</surname><given-names>D</given-names></name><name name-style="western"><surname>Coquet</surname><given-names>JM</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Light</surname><given-names>A</given-names></name><name name-style="western"><surname>D'Costa</surname><given-names>K</given-names></name><name name-style="western"><surname>Kallies</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>IL-21 regulates germinal center B cell differentiation and proliferation through a B cell-intrinsic mechanism</article-title>. <source>J Exp Med</source>. (<year>2010</year>) <volume>207</volume>:<fpage>365</fpage>&#8211;<lpage>78</lpage>. <pub-id pub-id-type="doi">10.1084/jem.20091777</pub-id><pub-id pub-id-type="pmid">20142430</pub-id><pub-id pub-id-type="pmcid">PMC2822601</pub-id></mixed-citation></ref><ref id="B115"><label>115.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Poholek</surname><given-names>AC</given-names></name><name name-style="western"><surname>Hansen</surname><given-names>K</given-names></name><name name-style="western"><surname>Hernandez</surname><given-names>SG</given-names></name><name name-style="western"><surname>Eto</surname><given-names>D</given-names></name><name name-style="western"><surname>Chandele</surname><given-names>A</given-names></name><name name-style="western"><surname>Weinstein</surname><given-names>JS</given-names></name><etal/></person-group>. <article-title>In vivo regulation of Bcl6 and T follicular helper cell development</article-title>. <source>J Immunol</source>. (<year>2010</year>) <volume>185</volume>:<fpage>313</fpage>&#8211;<lpage>26</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.0904023</pub-id><pub-id pub-id-type="pmid">20519643</pub-id><pub-id pub-id-type="pmcid">PMC2891136</pub-id></mixed-citation></ref><ref id="B116"><label>116.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Allen</surname><given-names>CD</given-names></name><name name-style="western"><surname>Okada</surname><given-names>T</given-names></name><name name-style="western"><surname>Cyster</surname><given-names>JG</given-names></name></person-group>. <article-title>Germinal-center organization and cellular dynamics</article-title>. <source>Immunity</source>. (<year>2007</year>) <volume>27</volume>:<fpage>190</fpage>&#8211;<lpage>202</lpage>. <pub-id pub-id-type="doi">10.1016/j.immuni.2007.07.009</pub-id><pub-id pub-id-type="pmid">17723214</pub-id><pub-id pub-id-type="pmcid">PMC2242846</pub-id></mixed-citation></ref><ref id="B117"><label>117.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weber</surname><given-names>TS</given-names></name></person-group>. <article-title>Cell cycle-Associated CXCR4 expression in germinal center B cells and its implications on affinity maturation</article-title>. <source>Front Immunol</source>. (<year>2018</year>) <volume>9</volume>:<fpage>1313</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2018.01313</pub-id><pub-id pub-id-type="pmid">29951060</pub-id><pub-id pub-id-type="pmcid">PMC6008520</pub-id></mixed-citation></ref><ref id="B118"><label>118.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Estes</surname><given-names>JD</given-names></name><name name-style="western"><surname>Keele</surname><given-names>BF</given-names></name><name name-style="western"><surname>Tenner-Racz</surname><given-names>K</given-names></name><name name-style="western"><surname>Racz</surname><given-names>P</given-names></name><name name-style="western"><surname>Redd</surname><given-names>MA</given-names></name><name name-style="western"><surname>Thacker</surname><given-names>TC</given-names></name><etal/></person-group>. <article-title>Follicular dendritic cell-mediated up-regulation of CXCR4 expression on CD4 T cells and HIV pathogenesis</article-title>. <source>J Immunol</source>. (<year>2002</year>) <volume>169</volume>:<fpage>2313</fpage>&#8211;<lpage>22</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.169.5.2313</pub-id><pub-id pub-id-type="pmid">12193696</pub-id></mixed-citation></ref><ref id="B119"><label>119.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bannard</surname><given-names>O</given-names></name><name name-style="western"><surname>Horton</surname><given-names>RM</given-names></name><name name-style="western"><surname>Allen</surname><given-names>CD</given-names></name><name name-style="western"><surname>An</surname><given-names>J</given-names></name><name name-style="western"><surname>Nagasawa</surname><given-names>T</given-names></name><name name-style="western"><surname>Cyster</surname><given-names>JG</given-names></name></person-group>. <article-title>Germinal center centroblasts transition to a centrocyte phenotype according to a timed program and depend on the dark zone for effective selection</article-title>. <source>Immunity</source>. (<year>2013</year>) <volume>39</volume>:<fpage>912</fpage>&#8211;<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1016/j.immuni.2013.08.038</pub-id><pub-id pub-id-type="pmid">24184055</pub-id><pub-id pub-id-type="pmcid">PMC3828484</pub-id></mixed-citation></ref><ref id="B120"><label>120.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rodda</surname><given-names>LB</given-names></name><name name-style="western"><surname>Bannard</surname><given-names>O</given-names></name><name name-style="western"><surname>Ludewig</surname><given-names>B</given-names></name><name name-style="western"><surname>Nagasawa</surname><given-names>T</given-names></name><name name-style="western"><surname>Cyster</surname><given-names>JG</given-names></name></person-group>. <article-title>Phenotypic and morphological properties of germinal center dark zone Cxcl12-expressing reticular cells</article-title>. <source>J Immunol</source>. (<year>2015</year>) <volume>195</volume>:<fpage>4781</fpage>&#8211;<lpage>91</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.1501191</pub-id><pub-id pub-id-type="pmid">26453751</pub-id><pub-id pub-id-type="pmcid">PMC4637241</pub-id></mixed-citation></ref><ref id="B121"><label>121.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Allen</surname><given-names>CD</given-names></name><name name-style="western"><surname>Ansel</surname><given-names>KM</given-names></name><name name-style="western"><surname>Low</surname><given-names>C</given-names></name><name name-style="western"><surname>Lesley</surname><given-names>R</given-names></name><name name-style="western"><surname>Tamamura</surname><given-names>H</given-names></name><name name-style="western"><surname>Fujii</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>Germinal center dark and light zone organization is mediated by CXCR4 and CXCR5</article-title>. <source>Nat Immunol</source>. (<year>2004</year>) <volume>5</volume>:<fpage>943</fpage>&#8211;<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1038/ni1100</pub-id><pub-id pub-id-type="pmid">15300245</pub-id></mixed-citation></ref><ref id="B122"><label>122.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barinov</surname><given-names>A</given-names></name><name name-style="western"><surname>Luo</surname><given-names>L</given-names></name><name name-style="western"><surname>Gasse</surname><given-names>P</given-names></name><name name-style="western"><surname>Meas-Yedid</surname><given-names>V</given-names></name><name name-style="western"><surname>Donnadieu</surname><given-names>E</given-names></name><name name-style="western"><surname>Arenzana-Seisdedos</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Essential role of immobilized chemokine CXCL12 in the regulation of the humoral immune response</article-title>. <source>Proc Natl Acad Sci USA</source>. (<year>2017</year>) <volume>114</volume>:<fpage>2319</fpage>&#8211;<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1611958114</pub-id><pub-id pub-id-type="pmid">28193885</pub-id><pub-id pub-id-type="pmcid">PMC5338526</pub-id></mixed-citation></ref><ref id="B123"><label>123.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Victora</surname><given-names>GD</given-names></name><name name-style="western"><surname>Schwickert</surname><given-names>TA</given-names></name><name name-style="western"><surname>Fooksman</surname><given-names>DR</given-names></name><name name-style="western"><surname>Kamphorst</surname><given-names>AO</given-names></name><name name-style="western"><surname>Meyer-Hermann</surname><given-names>M</given-names></name><name name-style="western"><surname>Dustin</surname><given-names>ML</given-names></name><etal/></person-group>. <article-title>Germinal center dynamics revealed by multiphoton microscopy with a photoactivatable fluorescent reporter</article-title>. <source>Cell</source>. (<year>2010</year>) <volume>143</volume>:<fpage>592</fpage>&#8211;<lpage>605</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2010.10.032</pub-id><pub-id pub-id-type="pmid">21074050</pub-id><pub-id pub-id-type="pmcid">PMC3035939</pub-id></mixed-citation></ref><ref id="B124"><label>124.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Allen</surname><given-names>CD</given-names></name><name name-style="western"><surname>Okada</surname><given-names>T</given-names></name><name name-style="western"><surname>Tang</surname><given-names>HL</given-names></name><name name-style="western"><surname>Cyster</surname><given-names>JG</given-names></name></person-group>. <article-title>Imaging of germinal center selection events during affinity maturation</article-title>. <source>Science</source>. (<year>2007</year>) <volume>315</volume>:<fpage>528</fpage>&#8211;<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1126/science.1136736</pub-id><pub-id pub-id-type="pmid">17185562</pub-id></mixed-citation></ref><ref id="B125"><label>125.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hauser</surname><given-names>AE</given-names></name><name name-style="western"><surname>Junt</surname><given-names>T</given-names></name><name name-style="western"><surname>Mempel</surname><given-names>TR</given-names></name><name name-style="western"><surname>Sneddon</surname><given-names>MW</given-names></name><name name-style="western"><surname>Kleinstein</surname><given-names>SH</given-names></name><name name-style="western"><surname>Henrickson</surname><given-names>SE</given-names></name><etal/></person-group>. <article-title>Definition of germinal-center B cell migration <italic toggle="yes">in vivo</italic> reveals predominant intrazonal circulation patterns</article-title>. <source>Immunity</source>. (<year>2007</year>) <volume>26</volume>:<fpage>655</fpage>&#8211;<lpage>67</lpage>. <pub-id pub-id-type="doi">10.1016/j.immuni.2007.04.008</pub-id><pub-id pub-id-type="pmid">17509908</pub-id></mixed-citation></ref><ref id="B126"><label>126.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schwickert</surname><given-names>TA</given-names></name><name name-style="western"><surname>Lindquist</surname><given-names>RL</given-names></name><name name-style="western"><surname>Shakhar</surname><given-names>G</given-names></name><name name-style="western"><surname>Livshits</surname><given-names>G</given-names></name><name name-style="western"><surname>Skokos</surname><given-names>D</given-names></name><name name-style="western"><surname>Kosco-Vilbois</surname><given-names>MH</given-names></name><etal/></person-group>. <article-title>In vivo imaging of germinal centres reveals a dynamic open structure</article-title>. <source>Nature</source>. (<year>2007</year>) <volume>446</volume>:<fpage>83</fpage>&#8211;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1038/nature05573</pub-id><pub-id pub-id-type="pmid">17268470</pub-id></mixed-citation></ref><ref id="B127"><label>127.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shulman</surname><given-names>Z</given-names></name><name name-style="western"><surname>Gitlin</surname><given-names>AD</given-names></name><name name-style="western"><surname>Weinstein</surname><given-names>JS</given-names></name><name name-style="western"><surname>Lainez</surname><given-names>B</given-names></name><name name-style="western"><surname>Esplugues</surname><given-names>E</given-names></name><name name-style="western"><surname>Flavell</surname><given-names>RA</given-names></name><etal/></person-group>. <article-title>Dynamic signaling by T follicular helper cells during germinal center B cell selection</article-title>. <source>Science</source>. (<year>2014</year>) <volume>345</volume>:<fpage>1058</fpage>&#8211;<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1126/science.1257861</pub-id><pub-id pub-id-type="pmid">25170154</pub-id><pub-id pub-id-type="pmcid">PMC4519234</pub-id></mixed-citation></ref><ref id="B128"><label>128.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van der Poel</surname><given-names>CE</given-names></name><name name-style="western"><surname>Bajic</surname><given-names>G</given-names></name><name name-style="western"><surname>Macaulay</surname><given-names>CW</given-names></name><name name-style="western"><surname>van den Broek</surname><given-names>T</given-names></name><name name-style="western"><surname>Ellson</surname><given-names>CD</given-names></name><name name-style="western"><surname>Bouma</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Follicular dendritic cells modulate germinal center B cell diversity through fcgammaRIIB</article-title>. <source>Cell Rep</source>. (<year>2019</year>) <volume>29</volume>:<fpage>2745</fpage>&#8211;<lpage>55</lpage>. <pub-id pub-id-type="doi">10.1016/j.celrep.2019.10.086</pub-id><pub-id pub-id-type="pmid">31775042</pub-id><pub-id pub-id-type="pmcid">PMC7015177</pub-id></mixed-citation></ref><ref id="B129"><label>129.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ersching</surname><given-names>J</given-names></name><name name-style="western"><surname>Efeyan</surname><given-names>A</given-names></name><name name-style="western"><surname>Mesin</surname><given-names>L</given-names></name><name name-style="western"><surname>Jacobsen</surname><given-names>JT</given-names></name><name name-style="western"><surname>Pasqual</surname><given-names>G</given-names></name><name name-style="western"><surname>Grabiner</surname><given-names>BC</given-names></name><etal/></person-group>. <article-title>Germinal center selection and affinity maturation require dynamic regulation of mTORC1 kinase</article-title>. <source>Immunity</source>. (<year>2017</year>) <volume>46</volume>:<fpage>1045</fpage>&#8211;<lpage>58</lpage>. <pub-id pub-id-type="doi">10.1016/j.immuni.2017.06.005</pub-id><pub-id pub-id-type="pmid">28636954</pub-id><pub-id pub-id-type="pmcid">PMC5526448</pub-id></mixed-citation></ref><ref id="B130"><label>130.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sethu</surname><given-names>S</given-names></name><name name-style="western"><surname>Govindappa</surname><given-names>K</given-names></name><name name-style="western"><surname>Alhaidari</surname><given-names>M</given-names></name><name name-style="western"><surname>Pirmohamed</surname><given-names>M</given-names></name><name name-style="western"><surname>Park</surname><given-names>K</given-names></name><name name-style="western"><surname>Sathish</surname><given-names>J</given-names></name></person-group>. <article-title>Immunogenicity to biologics: mechanisms, prediction and reduction</article-title>. <source>Arch Immunol Ther Exp</source>. (<year>2012</year>) <volume>60</volume>:<fpage>331</fpage>&#8211;<lpage>44</lpage>. <pub-id pub-id-type="doi">10.1007/s00005-012-0189-7</pub-id><pub-id pub-id-type="pmid">22930363</pub-id></mixed-citation></ref><ref id="B131"><label>131.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Winthrop</surname><given-names>KL</given-names></name><name name-style="western"><surname>Korman</surname><given-names>N</given-names></name><name name-style="western"><surname>Abramovits</surname><given-names>W</given-names></name><name name-style="western"><surname>Rottinghaus</surname><given-names>ST</given-names></name><name name-style="western"><surname>Tan</surname><given-names>H</given-names></name><name name-style="western"><surname>Gardner</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>T-cell-mediated immune response to pneumococcal conjugate vaccine (PCV-13) and tetanus toxoid vaccine in patients with moderate-to-severe psoriasis during tofacitinib treatment</article-title>. <source>J Am Acad Dermatol</source>. (<year>2018</year>) <volume>78</volume>:<fpage>1149</fpage>&#8211;<lpage>55</lpage>. <pub-id pub-id-type="doi">10.1016/j.jaad.2017.09.076</pub-id><pub-id pub-id-type="pmid">29080806</pub-id></mixed-citation></ref><ref id="B132"><label>132.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roth</surname><given-names>A</given-names></name><name name-style="western"><surname>Glaesener</surname><given-names>S</given-names></name><name name-style="western"><surname>Schutz</surname><given-names>K</given-names></name><name name-style="western"><surname>Meyer-Bahlburg</surname><given-names>A</given-names></name></person-group>. <article-title>Reduced number of transitional and naive B cells in addition to decreased BAFF levels in response to the T cell independent immunogen pneumovax(R)23</article-title>. <source>PLoS ONE</source>. (<year>2016</year>) <volume>11</volume>:<fpage>e0152215</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0152215</pub-id><pub-id pub-id-type="pmid">27031098</pub-id><pub-id pub-id-type="pmcid">PMC4816312</pub-id></mixed-citation></ref><ref id="B133"><label>133.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reding</surname><given-names>MT</given-names></name><name name-style="western"><surname>Lei</surname><given-names>S</given-names></name><name name-style="western"><surname>Lei</surname><given-names>H</given-names></name><name name-style="western"><surname>Green</surname><given-names>D</given-names></name><name name-style="western"><surname>Gill</surname><given-names>J</given-names></name><name name-style="western"><surname>Conti-Fine</surname><given-names>BM</given-names></name></person-group>. <article-title>Distribution of Th1- and Th2-induced anti-factor VIII IgG subclasses in congenital and acquired hemophilia patients</article-title>. <source>Thromb Haemost</source>. (<year>2002</year>) <volume>88</volume>:<fpage>568</fpage>&#8211;<lpage>75</lpage>. <pub-id pub-id-type="doi">10.1055/s-0037-1613257</pub-id><pub-id pub-id-type="pmid">12362225</pub-id></mixed-citation></ref><ref id="B134"><label>134.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reding</surname><given-names>MT</given-names></name></person-group>. <article-title>Immunological aspects of inhibitor development</article-title>. <source>Haemophilia</source>. (<year>2006</year>) <volume>12</volume>(<issue>Suppl. 6</issue>):<fpage>30</fpage>&#8211;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2516.2006.01363.x</pub-id><pub-id pub-id-type="pmid">17123391</pub-id></mixed-citation></ref><ref id="B135"><label>135.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dujmovic</surname><given-names>I</given-names></name><name name-style="western"><surname>Hegen</surname><given-names>H</given-names></name><name name-style="western"><surname>Paz</surname><given-names>P</given-names></name><name name-style="western"><surname>Croze</surname><given-names>E</given-names></name><name name-style="western"><surname>Deisenhammer</surname><given-names>F</given-names></name></person-group>. <article-title>Persistency of neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis treated with subcutaneous interferon-beta depends on antibody titers, IGG subclasses, and affinity maturation</article-title>. <source>J Interferon Cytokine Res</source>. (<year>2017</year>) <volume>37</volume>:<fpage>317</fpage>&#8211;<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1089/jir.2016.0080</pub-id><pub-id pub-id-type="pmid">28418769</pub-id></mixed-citation></ref><ref id="B136"><label>136.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jawa</surname><given-names>V</given-names></name><name name-style="western"><surname>Cousens</surname><given-names>LP</given-names></name><name name-style="western"><surname>Awwad</surname><given-names>M</given-names></name><name name-style="western"><surname>Wakshull</surname><given-names>E</given-names></name><name name-style="western"><surname>Kropshofer</surname><given-names>H</given-names></name><name name-style="western"><surname>De Groot</surname><given-names>AS</given-names></name></person-group>. <article-title>T-cell dependent immunogenicity of protein therapeutics: preclinical assessment and mitigation</article-title>. <source>Clin Immunol</source>. (<year>2013</year>) <volume>149</volume>:<fpage>534</fpage>&#8211;<lpage>55</lpage>. <pub-id pub-id-type="doi">10.1016/j.clim.2013.09.006</pub-id><pub-id pub-id-type="pmid">24263283</pub-id></mixed-citation></ref><ref id="B137"><label>137.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pratt</surname><given-names>KP</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>AR</given-names></name></person-group>. <article-title>B-cell and T-cell epitopes in anti-factor VIII immune responses</article-title>. <source>Clin Rev Allergy Immunol</source>. (<year>2009</year>) <volume>37</volume>:<fpage>80</fpage>&#8211;<lpage>95</lpage>. <pub-id pub-id-type="doi">10.1007/s12016-009-8120-7</pub-id><pub-id pub-id-type="pmid">19184559</pub-id></mixed-citation></ref><ref id="B138"><label>138.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lenders</surname><given-names>M</given-names></name><name name-style="western"><surname>Neusser</surname><given-names>LP</given-names></name><name name-style="western"><surname>Rudnicki</surname><given-names>M</given-names></name><name name-style="western"><surname>Nordbeck</surname><given-names>P</given-names></name><name name-style="western"><surname>Canaan-Kuhl</surname><given-names>S</given-names></name><name name-style="western"><surname>Nowak</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Dose-dependent effect of enzyme replacement therapy on neutralizing antidrug antibody titers and clinical outcome in patients with fabry disease</article-title>. <source>J Am Soc Nephrol</source>. (<year>2018</year>) <volume>29</volume>:<fpage>2879</fpage>&#8211;<lpage>89</lpage>. <pub-id pub-id-type="doi">10.1681/ASN.2018070740</pub-id><pub-id pub-id-type="pmid">30385651</pub-id><pub-id pub-id-type="pmcid">PMC6287863</pub-id></mixed-citation></ref><ref id="B139"><label>139.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bloem</surname><given-names>K</given-names></name><name name-style="western"><surname>Hernandez-Breijo</surname><given-names>B</given-names></name><name name-style="western"><surname>Martinez-Feito</surname><given-names>A</given-names></name><name name-style="western"><surname>Rispens</surname><given-names>T</given-names></name></person-group>. <article-title>Immunogenicity of therapeutic antibodies: monitoring antidrug antibodies in a clinical context</article-title>. <source>Ther Drug Monit</source>. (<year>2017</year>) <volume>39</volume>:<fpage>327</fpage>&#8211;<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1097/FTD.0000000000000404</pub-id><pub-id pub-id-type="pmid">28463887</pub-id></mixed-citation></ref><ref id="B140"><label>140.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Akhgar</surname><given-names>A</given-names></name><name name-style="western"><surname>Li</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Yu</surname><given-names>B</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C</given-names></name><name name-style="western"><surname>Lee</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>Selection of a ligand-binding neutralizing antibody assay for benralizumab: comparison with an antibody-dependent cell-mediated cytotoxicity (ADCC) cell-based assay</article-title>. <source>AAPS J</source>. (<year>2018</year>) <volume>20</volume>:<fpage>49</fpage>. <pub-id pub-id-type="doi">10.1208/s12248-018-0207-8</pub-id><pub-id pub-id-type="pmid">29541868</pub-id></mixed-citation></ref><ref id="B141"><label>141.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Domachowske</surname><given-names>JB</given-names></name><name name-style="western"><surname>Khan</surname><given-names>AA</given-names></name><name name-style="western"><surname>Esser</surname><given-names>MT</given-names></name><name name-style="western"><surname>Jensen</surname><given-names>K</given-names></name><name name-style="western"><surname>Takas</surname><given-names>T</given-names></name><name name-style="western"><surname>Villafana</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Safety, tolerability and pharmacokinetics of medi8897, an extended half-life single-dose respiratory syncytial virus prefusion f-targeting monoclonal antibody administered as a single dose to healthy preterm infants</article-title>. <source>Pediatr Infect Dis J</source>. (<year>2018</year>) <volume>37</volume>:<fpage>886</fpage>&#8211;<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1097/INF.0000000000001916</pub-id><pub-id pub-id-type="pmid">29373476</pub-id><pub-id pub-id-type="pmcid">PMC6133204</pub-id></mixed-citation></ref><ref id="B142"><label>142.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Schie</surname><given-names>KA</given-names></name><name name-style="western"><surname>Hart</surname><given-names>MH</given-names></name><name name-style="western"><surname>de Groot</surname><given-names>ER</given-names></name><name name-style="western"><surname>Kruithof</surname><given-names>S</given-names></name><name name-style="western"><surname>Aarden</surname><given-names>LA</given-names></name><name name-style="western"><surname>Wolbink</surname><given-names>GJ</given-names></name><etal/></person-group><article-title>The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region</article-title>. <source>Ann Rheum Dis</source>. (<year>2015</year>) <volume>74</volume>:<fpage>311</fpage>&#8211;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1136/annrheumdis-2014-206237</pub-id><pub-id pub-id-type="pmid">25342759</pub-id></mixed-citation></ref><ref id="B143"><label>143.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lenders</surname><given-names>M</given-names></name><name name-style="western"><surname>Schmitz</surname><given-names>B</given-names></name><name name-style="western"><surname>Brand</surname><given-names>SM</given-names></name><name name-style="western"><surname>Foell</surname><given-names>D</given-names></name><name name-style="western"><surname>Brand</surname><given-names>E</given-names></name></person-group>. <article-title>Characterization of drug-neutralizing antibodies in patients with fabry disease during infusion</article-title>. <source>J Allergy Clin Immunol</source>. (<year>2018</year>) <volume>141</volume>:<fpage>2289</fpage>&#8211;<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1016/j.jaci.2017.12.1001</pub-id><pub-id pub-id-type="pmid">29421273</pub-id></mixed-citation></ref><ref id="B144"><label>144.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cassotta</surname><given-names>A</given-names></name><name name-style="western"><surname>Mikol</surname><given-names>V</given-names></name><name name-style="western"><surname>Bertrand</surname><given-names>T</given-names></name><name name-style="western"><surname>Pouzieux</surname><given-names>S</given-names></name><name name-style="western"><surname>Le Parc</surname><given-names>J</given-names></name><name name-style="western"><surname>Ferrari</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>A single T cell epitope drives the neutralizing anti-drug antibody response to natalizumab in multiple sclerosis patients</article-title>. <source>Nat Med</source>. (<year>2019</year>) <volume>25</volume>:<fpage>1402</fpage>&#8211;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1038/s41591-019-0568-2</pub-id><pub-id pub-id-type="pmid">31501610</pub-id><pub-id pub-id-type="pmcid">PMC6795539</pub-id></mixed-citation></ref><ref id="B145"><label>145.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Antonelli</surname><given-names>G</given-names></name><name name-style="western"><surname>Dianzani</surname><given-names>F</given-names></name></person-group>. <article-title>Development of antibodies to interferon beta in patients: technical and biological aspects</article-title>. <source>Eur Cytokine Netw</source>. (<year>1999</year>) <volume>10</volume>:<fpage>413</fpage>&#8211;<lpage>22</lpage>.<pub-id pub-id-type="pmid">10477398</pub-id></mixed-citation></ref><ref id="B146"><label>146.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hermeling</surname><given-names>S</given-names></name><name name-style="western"><surname>Crommelin</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Schellekens</surname><given-names>H</given-names></name><name name-style="western"><surname>Jiskoot</surname><given-names>W</given-names></name></person-group>. <article-title>Structure-immunogenicity relationships of therapeutic proteins</article-title>. <source>Pharm Res</source>. (<year>2004</year>) <volume>21</volume>:<fpage>897</fpage>&#8211;<lpage>903</lpage>. <pub-id pub-id-type="doi">10.1023/B:PHAM.0000029275.41323.a6</pub-id><pub-id pub-id-type="pmid">15212151</pub-id></mixed-citation></ref><ref id="B147"><label>147.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Batista</surname><given-names>FD</given-names></name><name name-style="western"><surname>Harwood</surname><given-names>NE</given-names></name></person-group>. <article-title>The who, how and where of antigen presentation to B cells</article-title>. <source>Nat Rev Immunol</source>. (<year>2009</year>) <volume>9</volume>:<fpage>15</fpage>&#8211;<lpage>27</lpage>. <pub-id pub-id-type="doi">10.1038/nri2454</pub-id><pub-id pub-id-type="pmid">19079135</pub-id></mixed-citation></ref><ref id="B148"><label>148.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Depoil</surname><given-names>D</given-names></name><name name-style="western"><surname>Weber</surname><given-names>M</given-names></name><name name-style="western"><surname>Treanor</surname><given-names>B</given-names></name><name name-style="western"><surname>Fleire</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Carrasco</surname><given-names>YR</given-names></name><name name-style="western"><surname>Harwood</surname><given-names>NE</given-names></name><etal/></person-group>. <article-title>Early events of B cell activation by antigen</article-title>. <source>Sci Signal</source>. (<year>2009</year>) <volume>2</volume>:<fpage>pt1</fpage>. <pub-id pub-id-type="doi">10.1126/scisignal.263pt1</pub-id><pub-id pub-id-type="pmid">19318623</pub-id></mixed-citation></ref><ref id="B149"><label>149.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mascola</surname><given-names>JR</given-names></name><name name-style="western"><surname>Haynes</surname><given-names>BF</given-names></name></person-group>. <article-title>HIV-1 neutralizing antibodies: understanding nature's pathways</article-title>. <source>Immunol Rev</source>. (<year>2013</year>) <volume>254</volume>:<fpage>225</fpage>&#8211;<lpage>44</lpage>. <pub-id pub-id-type="doi">10.1111/imr.12075</pub-id><pub-id pub-id-type="pmid">23772623</pub-id><pub-id pub-id-type="pmcid">PMC3738265</pub-id></mixed-citation></ref><ref id="B150"><label>150.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gitlin</surname><given-names>AD</given-names></name><name name-style="western"><surname>Shulman</surname><given-names>Z</given-names></name><name name-style="western"><surname>Nussenzweig</surname><given-names>MC</given-names></name></person-group>. <article-title>Clonal selection in the germinal centre by regulated proliferation and hypermutation</article-title>. <source>Nature</source>. (<year>2014</year>) <volume>509</volume>:<fpage>637</fpage>&#8211;<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1038/nature13300</pub-id><pub-id pub-id-type="pmid">24805232</pub-id><pub-id pub-id-type="pmcid">PMC4271732</pub-id></mixed-citation></ref><ref id="B151"><label>151.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gitlin</surname><given-names>AD</given-names></name><name name-style="western"><surname>Mayer</surname><given-names>CT</given-names></name><name name-style="western"><surname>Oliveira</surname><given-names>TY</given-names></name><name name-style="western"><surname>Shulman</surname><given-names>Z</given-names></name><name name-style="western"><surname>Jones</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Koren</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Humoral immunity. T cell help controls the speed of the cell cycle in germinal center B cells</article-title>. <source>Science</source>. (<year>2015</year>) <volume>349</volume>:<fpage>643</fpage>&#8211;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1126/science.aac4919</pub-id><pub-id pub-id-type="pmid">26184917</pub-id><pub-id pub-id-type="pmcid">PMC4809261</pub-id></mixed-citation></ref><ref id="B152"><label>152.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tokatlian</surname><given-names>T</given-names></name><name name-style="western"><surname>Read</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Jones</surname><given-names>CA</given-names></name><name name-style="western"><surname>Kulp</surname><given-names>DW</given-names></name><name name-style="western"><surname>Menis</surname><given-names>S</given-names></name><name name-style="western"><surname>Chang</surname><given-names>JYH</given-names></name><etal/></person-group>. <article-title>Innate immune recognition of glycans targets HIV nanoparticle immunogens to germinal centers</article-title>. <source>Science</source>. (<year>2019</year>) <volume>363</volume>:<fpage>649</fpage>&#8211;<lpage>54</lpage>. <pub-id pub-id-type="doi">10.1126/science.aat9120</pub-id><pub-id pub-id-type="pmid">30573546</pub-id><pub-id pub-id-type="pmcid">PMC6420719</pub-id></mixed-citation></ref><ref id="B153"><label>153.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roco</surname><given-names>JA</given-names></name><name name-style="western"><surname>Mesin</surname><given-names>L</given-names></name><name name-style="western"><surname>Binder</surname><given-names>SC</given-names></name><name name-style="western"><surname>Nefzger</surname><given-names>C</given-names></name><name name-style="western"><surname>Gonzalez-Figueroa</surname><given-names>P</given-names></name><name name-style="western"><surname>Canete</surname><given-names>PF</given-names></name><etal/></person-group>. <article-title>Class-switch recombination occurs infrequently in germinal centers</article-title>. <source>Immunity</source>. (<year>2019</year>) <volume>51</volume>:<fpage>337</fpage>&#8211;<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1016/j.immuni.2019.07.001</pub-id><pub-id pub-id-type="pmid">31375460</pub-id><pub-id pub-id-type="pmcid">PMC6914312</pub-id></mixed-citation></ref><ref id="B154"><label>154.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Canete</surname><given-names>PF</given-names></name><name name-style="western"><surname>Sweet</surname><given-names>RA</given-names></name><name name-style="western"><surname>Gonzalez-Figueroa</surname><given-names>P</given-names></name><name name-style="western"><surname>Papa</surname><given-names>I</given-names></name><name name-style="western"><surname>Ohkura</surname><given-names>N</given-names></name><name name-style="western"><surname>Bolton</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Regulatory roles of IL-10-producing human follicular T cells</article-title>. <source>J Exp Med</source>. (<year>2019</year>) <volume>216</volume>:<fpage>1843</fpage>&#8211;<lpage>56</lpage>. <pub-id pub-id-type="doi">10.1084/jem.20190493</pub-id><pub-id pub-id-type="pmid">31209070</pub-id><pub-id pub-id-type="pmcid">PMC6683995</pub-id></mixed-citation></ref><ref id="B155"><label>155.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Austin</surname><given-names>JW</given-names></name><name name-style="western"><surname>Buckner</surname><given-names>CM</given-names></name><name name-style="western"><surname>Kardava</surname><given-names>L</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Melson</surname><given-names>VA</given-names></name><etal/></person-group><article-title>Overexpression of T-bet in HIV infection is associated with accumulation of B cells outside germinal centers and poor affinity maturation</article-title>. <source>Sci Transl Med</source>. (<year>2019</year>) <volume>27</volume>:<fpage>11</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.aax0904</pub-id><pub-id pub-id-type="pmcid">PMC7479651</pub-id><pub-id pub-id-type="pmid">31776286</pub-id></mixed-citation></ref><ref id="B156"><label>156.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mazor</surname><given-names>R</given-names></name><name name-style="western"><surname>Crown</surname><given-names>D</given-names></name><name name-style="western"><surname>Addissie</surname><given-names>S</given-names></name><name name-style="western"><surname>Jang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kaplan</surname><given-names>G</given-names></name><name name-style="western"><surname>Pastan</surname><given-names>I</given-names></name></person-group>. <article-title>Elimination of murine and human T-cell epitopes in recombinant immunotoxin eliminates neutralizing and anti-drug antibodies in vivo</article-title>. <source>Cell Mol Immunol</source>. (<year>2017</year>) <volume>14</volume>:<fpage>432</fpage>&#8211;<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1038/cmi.2015.91</pub-id><pub-id pub-id-type="pmid">26477977</pub-id><pub-id pub-id-type="pmcid">PMC5423085</pub-id></mixed-citation></ref><ref id="B157"><label>157.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cirelli</surname><given-names>KM</given-names></name><name name-style="western"><surname>Carnathan</surname><given-names>DG</given-names></name><name name-style="western"><surname>Nogal</surname><given-names>B</given-names></name><name name-style="western"><surname>Martin</surname><given-names>JT</given-names></name><name name-style="western"><surname>Rodriguez</surname><given-names>OL</given-names></name><name name-style="western"><surname>Upadhyay</surname><given-names>AA</given-names></name><etal/></person-group>. <article-title>Slow delivery immunization enhances HIV neutralizing antibody and germinal center responses via modulation of immunodominance</article-title>. <source>Cell</source>. (<year>2020</year>) <volume>180</volume>:<fpage>206</fpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2019.12.027</pub-id><pub-id pub-id-type="pmid">31923396</pub-id><pub-id pub-id-type="pmcid">PMC7009795</pub-id></mixed-citation></ref><ref id="B158"><label>158.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moyer</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Kato</surname><given-names>Y</given-names></name><name name-style="western"><surname>Abraham</surname><given-names>W</given-names></name><name name-style="western"><surname>Chang</surname><given-names>JYH</given-names></name><name name-style="western"><surname>Kulp</surname><given-names>DW</given-names></name><name name-style="western"><surname>Watson</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>Engineered immunogen binding to alum adjuvant enhances humoral immunity</article-title>. <source>Nat Med</source>. (<year>2020</year>) <volume>26</volume>:<fpage>430</fpage>&#8211;<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1038/s41591-020-0753-3</pub-id><pub-id pub-id-type="pmid">32066977</pub-id><pub-id pub-id-type="pmcid">PMC7069805</pub-id></mixed-citation></ref><ref id="B159"><label>159.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thompson</surname><given-names>HL</given-names></name><name name-style="western"><surname>Smithey</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Surh</surname><given-names>CD</given-names></name><name name-style="western"><surname>Nikolich-Zugich</surname><given-names>J</given-names></name></person-group>. <article-title>Functional and homeostatic impact of age-related changes in lymph node stroma</article-title>. <source>Front Immunol</source>. (<year>2017</year>) <volume>8</volume>:<fpage>706</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2017.00706</pub-id><pub-id pub-id-type="pmid">28659930</pub-id><pub-id pub-id-type="pmcid">PMC5469916</pub-id></mixed-citation></ref><ref id="B160"><label>160.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nikolich-Zugich</surname><given-names>J</given-names></name></person-group><article-title>The twilight of immunity: emerging concepts in aging of the immune system</article-title>. <source>Nat Immunol</source>. (<year>2018</year>) <volume>19</volume>:<fpage>10</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1038/s41590-017-0006-x</pub-id><pub-id pub-id-type="pmid">29242543</pub-id></mixed-citation></ref><ref id="B161"><label>161.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shankwitz</surname><given-names>K</given-names></name><name name-style="western"><surname>Pallikkuth</surname><given-names>S</given-names></name><name name-style="western"><surname>Sirupangi</surname><given-names>T</given-names></name><name name-style="western"><surname>Kirk Kvistad</surname><given-names>D</given-names></name><name name-style="western"><surname>Russel</surname><given-names>KB</given-names></name><name name-style="western"><surname>Pahwa</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Compromised steady-state germinal center activity with age in nonhuman primates</article-title>. <source>Aging Cell</source>. (<year>2019</year>) <volume>19</volume>:<fpage>e13087</fpage>. <pub-id pub-id-type="doi">10.1111/acel.13087</pub-id><pub-id pub-id-type="pmid">31840398</pub-id><pub-id pub-id-type="pmcid">PMC6996951</pub-id></mixed-citation></ref><ref id="B162"><label>162.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Estes</surname><given-names>JD</given-names></name></person-group>. <article-title>Pathobiology of HIV/SIV-associated changes in secondary lymphoid tissues</article-title>. <source>Immunol Rev</source>. (<year>2013</year>) <volume>254</volume>:<fpage>65</fpage>&#8211;<lpage>77</lpage>. <pub-id pub-id-type="doi">10.1111/imr.12070</pub-id><pub-id pub-id-type="pmid">23772615</pub-id><pub-id pub-id-type="pmcid">PMC6066369</pub-id></mixed-citation></ref><ref id="B163"><label>163.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Petrovas</surname><given-names>C</given-names></name><name name-style="western"><surname>Yamamoto</surname><given-names>T</given-names></name><name name-style="western"><surname>Gerner</surname><given-names>MY</given-names></name><name name-style="western"><surname>Boswell</surname><given-names>KL</given-names></name><name name-style="western"><surname>Wloka</surname><given-names>K</given-names></name><name name-style="western"><surname>Smith</surname><given-names>EC</given-names></name><etal/></person-group>. <article-title>CD4 T follicular helper cell dynamics during SIV infection</article-title>. <source>J Clin Invest</source>. (<year>2012</year>) <volume>122</volume>:<fpage>3281</fpage>&#8211;<lpage>94</lpage>. <pub-id pub-id-type="doi">10.1172/JCI63039</pub-id><pub-id pub-id-type="pmid">22922258</pub-id><pub-id pub-id-type="pmcid">PMC3428091</pub-id></mixed-citation></ref><ref id="B164"><label>164.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Meer</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Kooijman</surname><given-names>M</given-names></name><name name-style="western"><surname>Brinks</surname><given-names>V</given-names></name><name name-style="western"><surname>Gispen-de Wied</surname><given-names>CC</given-names></name><name name-style="western"><surname>Silva-Lima</surname><given-names>B</given-names></name><name name-style="western"><surname>Moors</surname><given-names>EH</given-names></name><etal/></person-group>. <article-title>Immunogenicity of mAbs in non-human primates during nonclinical safety assessment</article-title>. <source>MAbs</source>. (<year>2013</year>) <volume>5</volume>:<fpage>810</fpage>&#8211;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.4161/mabs.25234</pub-id><pub-id pub-id-type="pmid">23924803</pub-id><pub-id pub-id-type="pmcid">PMC3851233</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>